2019 AVBCC Summit

AVBCC

October 16-17, 2019 | New York Athletic Club, New York, NY

Save the date! The Association for Value-Based Cancer Care (AVBCC) invites you to attend the 2019 AVBCC Summit in New York, NY on October 16-17, 2019. This is a prime opportunity to gain a thorough understanding of the evolution of the value equation as it relates to cancer therapies and discover how to implement, improve, and sustain your company or institution, while improving access for patients and ultimately patient care.

Top 3 Reasons to Attend the 2019 AVBCC Conference

  • Stay competitive in the ever-changing field of oncology participating in sessions on topics including Health Policy, Telemedicine, Practice Management, Oncology Specialty Pharmacy and Supply Chain, and more.
  • Learn from stakeholders within the cancer care spectrum, including practitioners, pharmacists, payers, and policymakers to improve patient care and maximize patient access and outcomes through care coordination.
  • Network with nationally recognized experts, faculty speakers, panelists, key opinion leaders, C-suite executives, and managers to exchange best practices in advanced value-based performance and quality measures in cancer care.

No other meeting brings together so many key perspectives in cancer care.


2018 AVBCC Conference Faculty

Click a name below to view full biography.


Edward Abrahams, PhD

President, Personalized Medicine Coalition

Edward Abrahams is President of Personalized Medicine Coalition. Representing innovators, scientists, patients, providers, and payers, the Personalized Medicine Coalition promotes the understanding and adoption of personalized medicine concepts, services, and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 200 today.

Previously, he was Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier, he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.

He worked for 7 years for the US Congress, including as a legislative assistant to Senator Lloyd Bentsen, as an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as an American Association for the Advancement of Science Congressional Fellow for Representative Edward J. Markey.

The author of numerous researches, he serves on the Editorial Board of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.

Maggie Adamski

Senior Director, Global Patient Insights and Engagements, ICON

Maggie Adamski is Senior Director of Global Patient Insights and Engagement at ICON. She has more than 25 years of experience in a variety of roles in the pharmaceutical industry, including clinical trial patient recruitment and retention, patient engagement technologies, and eLearning platforms. She has been involved in the development and facilitation of patient and key opinion leader workshops, and has collaborated with patient advocacy groups. As both a clinical trial participant and patient advocate, she is passionate about bringing the patient voice into pharmaceutical research.

Cheryl Allen, BSPharm, MBA

Vice President, Industry Relations, Diplomat

In her role as Vice President of Industry Relations at Diplomat Specialty Pharmacy, Cheryl Allen works with pharmaceutical manufacturers in finding partnerships and crafting healthcare solutions. Specifically, she helps to identify new opportunities within the pharmaceutical industry, then collaborates with manufacturers to design services and distribution solutions that support their patients’ journey.

Cheryl brings more than 25 years of industry experience, with work in independent and specialty pharmacies, as well as in managed care consulting and healthcare information technology. Before joining Diplomat Specialty Pharmacy in July 2011, Cheryl worked as Senior Director, Clinical Services, Sanovia Corporation, Philadelphia, PA, where she managed new product development and sales support. Prior to her tenure at Sanovia, she held roles with Priority Healthcare in Eddystone, PA, as Pharmacist-in-Charge, Oncology, and Lead Pharmacist, Pain Management. Cheryl also founded C. Allen & Associates, a firm focused on managed care consulting, and Eden Drug Company, an independent pharmacy.

Cheryl earned her Bachelor of Science in pharmacy at McWhorter School of Pharmacy, Samford University, Birmingham, AL, and her Master’s in business administration at Haub School of Business, Saint Joseph’s University, Philadelphia, PA, with a focus on pharmaceutical and healthcare marketing.

Rachel Anhorn, PharmD

Director, Payer Policy & Health Outcomes, Foundation Medicine

Regional Scientific Manager, Health Outcomes & Phamacoeconomics, Hospira

Rachel Anhorn is Director, Payer Policy & Health Outcomes, Payer Relations and Reimbursement Team, Foundation Medicine, Cambridge, MA, where she leads the development of US Health Economics and Outcomes Research initiatives and is focused on payer education about the unique clinical value of comprehensive genomic profiling. Her professional interests include helping shape healthcare policy to promote the value of oncology diagnostics and genomically matched precision treatment to improve outcomes and cost-effectiveness of cancer care for all stakeholders.

Previous to her role at Foundation Medicine, she worked as Medical Director, Biosimilars Group, Pfizer, Boston, MA; and at Boehringer Ingelheim, as Associate Director, Health Economics & Outcomes Research, where her team provided support for idiopathic pulmonary fibrosis, oncology, chronic obstructive pulmonary disease, diabetes, and atrial fibrillation, and as Medical Science Liaison, Metabolics, supporting the metabolic disease programs in endocrinology and nephrology.

Rachel received her education through Rutgers, The State University of New Jersey’s Postdoctoral Fellowship, her Bachelor’s in medical strategy and scientific communications, her PharmD at the University of Minnesota College of Pharmacy, Minneapolis, and her Bachelor of Science in biochemistry, at the University of Wisconsin-River Falls.

Sheila Arquette, RPh

Executive Director, National Association of Specialty Pharmacy

Sheila Arquette is Executive Director of the National Association of Specialty Pharmacy (NASP), where she coordinates and facilitates the networking-focused annual meeting and exposition, provides the required organizational structure to support NASP, and advocates for public policies and state and federal legislation to ensure appropriate patient access to specialty medications and related patient care support services. Prior to joining NASP in February 2017, she was Director of Pharmacy Services at Independent Health.

She has extensive practical and leadership experience in retail pharmacy, hospital pharmacy, long-term care consulting and dispensing, in addition to managed care, PBM operations, and specialty pharmacy. She is a regular speaker and participant at national pharmacy conferences, roundtables, and industry meetings.

She has recently been appointed to the University of Pittsburgh’s Master of Science in Pharmacy Business Administration Executive Steering Board and serves as a clinical pharmacist consultant to HealthNow New York. She is the host of the NASP podcast on the Pharmacy Podcast Network, was elected to the NASP Board of Directors, and received the NASP Distinguished Service Award in September 2016. She also is a long-standing member of the Academy of Managed Care Pharmacy.

She holds a Bachelor of Science degree in pharmacy from the State University of New York at Buffalo School of Pharmacy.

Peter B. Bach, MD, MAPP

Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Peter B. Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. He is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients. He described a 100-fold increase in cancer drug prices since 1965 after adjusting for inflation, and that the cost of an additional year of life from a cancer treatment increases by $8500 each year.

In 2012, he and other physicians at Memorial Sloan Kettering drew attention to the high price of a newly approved cancer drug, and announced his hospital’s unprecedented move not to offer it to patients because of its high price tag with no notable improved clinical outcomes. The drug price was later cut in half by the manufacturer.

His work in lung cancer screening has led to the development of several lung cancer screening guidelines and one of the first-ever risk-prediction models for this disease. He has also proposed a number of strategies for Medicare to link payment to the value of healthcare services delivered.

He has been inducted into the National Academy of Medicine, the American Society of Clinical Investigators, and the Johns Hopkins University Society of Scholars. He served as Senior Advisor for Cancer Policy at the Centers for Medicare & Medicaid Services in 2005 and 2006.

He has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He has also written numerous healthcare-related op-eds and been featured in mainstream media outlets, including the New York Times, New York magazine, Wall Street Journal, Forbes, National Public Radio, and 60 Minutes.

He completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar. He has been a faculty member in Memorial Sloan Kettering’s Department of Epidemiology and Biostatistics since 1998 and a Senior Scholar at the International Agency for Research on Cancer since 2008.

Ray Bailey, RPh

Pharmacy Director, Florida Cancer Specialists

Ray Bailey is Pharmacy Director for Florida Cancer Specialists in Fort Myers. He is responsible for overseeing the operations of Florida Cancer Specialists’ Oncology Specialty Pharmacy, Rx To Go, which includes financial management, business development, new drug access, purchasing contracts, and overall formulary management. In 2010, he was promoted to this position 2 years after joining the company as the Pharmacy Manager.

Prior to his current role, he was General Manager of Walgreens/OptionCare of Southwest Florida. He was also Staff Pharmacist at Naples Community Hospital; owner of Pine Island Pharmacy; and President and Chief Executive Officer-Owner of OptionCare of Southwest Florida, a national franchise of home infusion pharmacy services.

He holds professional memberships and associations in the Community Oncology Alliance, an Advisory Board Member of the Community Oncology Pharmacy Alliance, an Advisory Board Member of the National Community Oncology Dispensing Association, the Hematology Oncology Pharmacist Association, and the Florida Pharmacy Association.

He earned his bachelor’s and graduate degrees in pharmacy from the University of Georgia.

Craig Beardsley

Pool Program Director, Swim Across America

Craig Beardsley is Pool Program Director for Swim Across America, a charitable organization that raises funds for cancer research. He has been an active participant in Swim Across America’s events since 1987.

He was heavily favored to win the 200-meter butterfly as a member of the 1980 US Olympic Team, only to be forced from competition when politics intervened, and the United States boycotted Moscow’s Summer Olympic Games. Between 1980 and 1983, he held the World and the American Records in the 200-meter butterfly, and he won Gold Medals at the Pan American Games in 1979 and 1983. A 9-time US National Champion, he captured 2 more Gold Medals in the same event at the National Collegiate Athletic Association Championships while an All-American at the University of Florida.

Craig graduated from the University of Florida with a bachelor degree in management and was inducted into the University of Florida Athletic Hall of Fame as a “Gator Great.” He and his wife live in New Jersey with their 2 children, Carter and Caroline.

Al Benson III, MD, FACP, FASCO

Chair, Scientific Review Committee, Robert H. Lurie Comprehensive Cancer Center

Professor, Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University

Al Benson III is Professor of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, and Chair, Scientific Review Committee, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. He is Chair of the National Comprehensive Cancer Network (NCCN) Hepatobiliary Guidelines Panel and of the Colon, Rectal and Anal Panel, and a member of the Pancreatic Cancer and Neuroendocrine panels. In addition, he is Attending Physician at Northwestern Memorial Hospital, Staff Physician at Jesse Brown VA Medical Center, and Consultant to the Rehabilitation Institute of Chicago.

He earned his medical degree at the State University of New York at Buffalo following which he completed an Internal Medicine Residency at the University of Wisconsin Hospitals in Madison. He was Assistant Professor of Medicine at the University of Illinois and Co-Medical Director for the National Public Health Service in Champaign, IL. He then served as Clinical Oncology and Research Fellow at the University of Wisconsin Clinical Cancer Center, where he received an American Cancer Society Fellowship Award.

Active on numerous professional committees, he often serves as an officer. He is a recipient of the American Society of Clinical Oncology (ASCO) Statesman Award and has served on a number of committees. He has been a member of the Task Force on Quality of Cancer Care, co-chair of ASCO’s Colorectal Cancer Guidelines Subcommittee, the Stage II Colon Cancer Guidelines Panel, and the Guidelines Panel for use of Radiofrequency Ablation for Colorectal Cancer, for example. He also is immediate past chair of the ECOG-ACRIN Gastrointestinal Committee, current chair of the Data Monitoring Committee, and a member of the NCI Rectal/Anal Task Force. He is chair of the International Rare Cancers Initiative, Anal Cancer Committee, and a member of the Small Intestinal Cancer Committee. In addition, he is past president of the Illinois Medical Oncology Society, past president of the Association of Community Cancer Centers, executive committee member and past chair of the Board of Directors of NCCN, and a member of the Board of Directors of the NCCN Foundation. He is past president of the International Society of Gastrointestinal Oncology. He is a member of the Executive Committee of the Patient Advocate Foundation, the National Patient Advocate Foundation (president), and Scientific Advisory Committee of Friends of Cancer Research. Additionally, he is a medical advisory board member for Debbie’s Dream Foundation: Curing Stomach Cancer as well as Fight Colorectal Cancer.

He is on the editorial board of the Journal of the National Comprehensive Cancer Network, American Health & Drug Benefits, Personalized Medicine in Oncology, Journal of Comparative Effectiveness Research, and Gastrointestinal Cancer Research, among others.

His research is primarily in the areas of gastrointestinal cancer clinical trials, biologic therapies, phase 1 cancer clinical trials, health services research, and cancer guideline development. He has authored or co-authored numerous reports, reviews, and book chapters focusing on these topics. His research in biologics, cancer therapy, and cancer prevention has been awarded funding from a variety of sources, including the National Institutes of Health.

His most recent national awards include the NCCN Rodger Winn Award and the ACCC Outstanding Achievement in Clinical Research Award.

Kimberly L. Blackwell, MD

Vice President, Early Phase Clinical Research and Immuno-Oncology, Eli Lilly and Company

Kimberly L. Blackwell is Vice President, Early Phase Clinical Research and Immuno-Oncology, Eli Lilly and Company, where she oversees the clinical development teams for promising early-stage therapeutics. She has played a major role in developing therapies that represent revolutionary nonchemotherapy-based approaches for treating breast cancer. Her clinical and research interests include various topics in breast cancer, including endocrine therapy, novel HER2 therapies, breast cancer vaccines, and other experimental therapeutics. She has studied and served as the principal investigator on studies that led to regulatory approval of 4 cancer agents, including the first biosimilar treatment for cancer in the United States. Recently, her research interests have also included triple-negative breast cancer and cancer that has spread to the brain.

Prior to her role at Eli Lilly, she was Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University Medical Center for 24 years.

Due to her leadership, she has received numerous awards, including the Duke University Distinguished Alumni in 2015, TIME Magazine’s 100 Most Influential People in the World in 2013, the Young Investigator Award in Breast Cancer from the National Cancer Institute Specialized Program of Research Excellence, and the Joseph Greenfield Award for Mentorship of Clinical Research.

She is also Co-Director of the Duke University Cancer Program, Associate Director for Strategic Relations for the Duke Cancer Institute, Research Scholar for the Susan G. Komen Foundation, and Senior Strategist for the Duke Innovation and Entrepreneurship Program.

She received her medical degree from the Mayo Clinic Medical School, her residency in medicine at Duke University, and her fellowship in hematology/oncology at Duke University.

Douglas Bock, MBA

Partner, Archbow Consulting

Douglas Bock is a partner at Archbow Consulting, a strategic consulting practice for the pharmaceutical and biotechnology industry. He is frequently sought for his expertise in creating data-driven solutions to improve patient health outcomes worldwide. He advises clients on complex specialty product reimbursement, patient access programs, supply chain optimization, trade relations, and risk evaluation and mitigation strategies and risk management programs.

Douglas was also Co-Founder and Principal of a multinational firm dedicated to helping patients overcome the challenges of accessing pharmaceutical products worldwide.

He began his career working in operations at Merck Research Labs. From there he held a variety of sales, sales management, and marketing management positions at Merck and later at Solvay. He worked at Hoffmann-LaRoche in Licensing and US Commercial Operations. He has launch experience in more than 2 dozen therapeutic areas.

Douglas holds an Arts Baccalaureate in international relations from Colgate University, Hamilton, NY, and a Master of Business Administration from Yale University, New Haven, CT.

Jeffrey M. Bockman, PhD, EVP

Executive Vice President, Head of Oncology Practice, Defined Health

Jeffrey M. Bockman is Executive Vice President and leads the Oncology and Virology Practices at Defined Health. He has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at Defined Health. He often speaks at conferences on scientific and commercial issues in cancer, especially immuno-oncology.

Before joining Defined Health, he was Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories, and Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with 2 Nobel Prize recipients: Dr Sidney Altman on ribozymes and Dr Stanley Prusiner on prions. Dr Bockman holds 4 patents in the use of ribozymes.

He is a member of the Licensing Executives Society, American Association for Cancer Research, American Society of Clinical Oncology, American Society of Hematology, American Society of Gene and Cell Therapy, Society for Immunotherapy of Cancer, and New York Academy of Sciences.

He received a Bachelor of Arts in biology and literature from the University of California at San Diego, a PhD in medical microbiology from the University of California at Berkeley, and a Master of Arts in English and creative writing from New York University.

Rohit Borker, PhD

Vice President and Head, Health Economics and Outcomes Research, US Oncology, Novartis

Rohit Borker is currently Vice President and Head, Health Economics and Outcomes Research (HEOR), US Oncology at Novartis. In this role, he leads the HEOR organization in generation of evidence for US organized customers, including payers and integrated delivery networks. In addition, his team is also involved in innovative research relevant to the value of oncology care, real-world data and analytics, and patient-centered initiatives.

Before joining Novartis, he was with Boehringer Ingelheim’s HEOR group, leading their oncology and respiratory therapy areas, where he managed a team of health outcomes researchers with responsibilities to develop evidence in support of value proposition for Boehringer Ingelheim’s products. Prior to Boehringer Ingelheim, he was at GlaxoSmithKline, where he led a field team of Health Outcomes Liaisons with responsibilities for their General Medicine and Vaccine Portfolio. During this time, he also served on the National Quality Forum’s Oncology Technical Advisory Panel, which evaluated methodologies to assess resource utilization and cost as it relates to oncology management.

In addition to oncology, he has covered multiple therapeutic areas, including respiratory, nephrology, and autoimmune disorders.

He has multiple publications, including papers in Value in Health; Pharmacoeconomics; Clinical Genitourinary Cancer; BMC Cancer; Annals of Asthma, Allergy, & Immunology; and Journal of Health & Social Policy.

Prior to joining the industry, he completed his doctoral work at West Virginia University. His thesis evaluated breast cancer risk in the West Virginia Medicaid population using validated risk algorithms and developed economic models to estimate cost-effectiveness of chemopreventive strategy. During his doctoral work, he also served as the research lead for the Center for Disease Control and Prevention’s and American Pharmaceutical Association’s Pharmacy Immunization Project. His post-thesis work involves numerous database studies, including cost of event studies, early- and late-stage economic modeling, patient-reported outcomes application, and analyses. He was part of the original working group that eventually developed the COPD-Assessment Questionnaire.

Brian Bourbeau, MBA, LSSBB

Associate Director, Business Metrics and Analysis, American Society of Clinical Oncology

Brian Bourbeau is Associate Director, Business Metrics and Analysis, within the Clinical Affairs Department, of the American Society of Clinical Oncology (ASCO). In this role, Brian oversees various practice health initiatives, including PracticeNET, a reporting and benchmarking service for ASCO members.

Prior to ASCO, he was Director, Practice Operations, Oncology Hematology Care, Cincinnati, OH, where he oversaw quality programs, managed care, and revenue cycle operations. Brian’s experience with alternative payment models include multiple Medicare, Medicaid, and commercial programs. His experience includes quality and financial management positions with The Ohio State University, University of Cincinnati Medical Center, and Lee Memorial Health System.

He holds a Master of Business Administration from Franklin University, Columbus, as well as certifications in Lean, Six Sigma, and Business Intelligence.

Joel V. Brill, MD, FACP

Chief Medical Officer, Predictive Health

Joel V. Brill is Executive Clinician with more than 30 years of experience providing strategic leadership and medical oversight to large data-driven health organizations. He is skilled in strategy, development, and implementation of innovative health programs, products, and payment systems, with extensive experience in clinical practice, research, coverage, reimbursement, quality improvement, data analysis, bundled and episode payments, and accountable care.

He is board certified in internal medicine and gastroenterology. He is Chief Medical Officer of Predictive Health. He has run risk-bearing independent practice associations and physician-hospital organizations in California and Arizona, has held management positions, and currently participates on scientific advisory boards/committees for several managed care companies. He was Deputy Medical Director for the Beneficiary and Family Centered Care-National Coordinating Center Quality Improvement Organizations oversight project, was Section Editor for GI & Hepatology News, serves on the Editorial Advisory Board for several journals, and was Co-Founder of the American Gastrointestinal Association Center for GI Innovation and Technology.

He works extensively with the Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA) on coding, coverage, and reimbursement issues, and he co-chaired the Part D Medication Measures Technical Expert Panel for CMS. He participates in the Current Procedural Terminology Editorial Panel and the AMA Resource-Based Relative Value Scale Update Committee, and has introduced over 180 CPT coding proposals. He has published extensively on episode and bundled payment methodologies, and has developed and submitted advanced payment models to the Health and Human Services’ Physician Focused Payment Model Technical Advisory Committee for consideration under the Medicare Access and CHIP Reauthorization Act of 2015.

Dr Brill is Assistant Clinical Professor of Medicine at the University of Arizona College of Medicine, and Adjunct Assistant Professor of Medicine at Midwestern University. He has lectured at the School of Health Management & Policy at the W.P. Carey School of Business at Arizona State University.

He received his undergraduate Artium Baccalaureus in biology at the University of California, Los Angeles (UCLA), and his medical degree from the Rosalind Franklin University of Medicine and Science-Chicago Medical School. He completed his internship and residency in internal medicine at the UCLA-San Fernando Valley Program, and a fellowship in gastroenterology at Los Angeles County-USC Medical Center. He completed the Management Program for Health Care Organizations at the UCLA School of Public Health.

Barry Brooks, MD

Founding Partner and Hematologist/Oncologist, Texas Oncology

Barry Brooks is Practicing Hematologist/Oncologist and Founding Partner of Texas Oncology, the largest community oncology practice in the United States with over 450 physicians practicing in more than 1600 sites of service. His areas of expertise include oncology drug pricing, advancing and promoting evidence-based medicine, and improving access to cancer care.

He currently serves as Chair of the Pharmacy and Therapeutics Committee for The US Oncology Network and was an original member of The US Oncology Network’s Pathways Task Force. He serves as Co-Chair of The US Oncology Network’s Drug Contracting Committee, where he is continually engaged in conversations with biopharmaceutical manufacturers. He is active in public policy, advocating for cancer care in general and community oncology specifically.

Currently, he is pursuing a Master in Business Administration at The University of Texas at Dallas.

Danielle Bubnis

Senior Director, Advocacy, Leukemia & Lymphoma Society

Danielle Bubnis currently serves as Senior Director of Advocacy for the Leukemia & Lymphoma Society, Office of Public Policy. In this role, Danielle provides strategic leadership to the organization’s advocacy program, and manages a national, field-based team, developing advocacy initiatives to advance policies that support access to care for patients. Prior to this role, she worked extensively on issue-based advocacy campaigns in the mid-Atlantic and northeast regions of the United States, providing strategy and leadership to coalitions of patient advocacy groups, healthcare professionals, industry partners, and professional organizations. Her work also included developing and implementing volunteer-based advocacy networks across these regions.

Danielle is a licensed social worker and has spent her entire professional career supporting patients and their families living with a diagnosis of cancer. Prior to her work with the Office of Public Policy, Danielle served as Patient Services Manager at the Leukemia & Lymphoma Society, offering assessment and overall psychosocial support to patients with blood cancer and their family members throughout their cancer journey. In this role, she developed and coordinated patient support programs, which included family support groups, financial assistance, peer-to-peer support, and educational sessions. Before joining the Leukemia & Lymphoma Society team in central Pennsylvania as Patient Services Manager, she served as Oncology Social Worker at the Janet Weis Children’s Hospital in Danville, PA.

Danielle graduated from Dickinson College, Carlisle, PA, with a Bachelor of Science in psychology and mathematics and earned her Master’s degree in social work from Marywood University, Scranton, PA. She is currently a licensed social worker in the state of Pennsylvania.

Randy Burkholder

Vice President, Policy & Research, Pharmaceutical Research and Manufacturers of America

Randy Burkholder is Vice President, Policy and Research, Pharmaceutical Research and Manufacturers of America (PhRMA). He leads PhRMA work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered healthcare, including payment and delivery reform, quality measurement, appropriate use and patient adherence, evidence-based medicine and health technology assessment, value of innovation, and personalized medicine. He represents PhRMA at federal agencies and advisory bodies, including the Medicare Evidence Development and Coverage Advisory Committee, CMS’ Technical Expert Panel on Oncology, and the Federal Coordinating Council for Comparative Effectiveness Research. He also is a former member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care, and the advisory committee for the Turning the Tide Against Cancer initiative.

He has more than 20 years of experience in healthcare policy, advocacy, and communication in the medical technology and pharmaceutical industries.

Prior to joining PhRMA, he was Associate Vice President for Public Affairs at AdvaMed, the leading association of the medical device and diagnostics industries.

Rob Butcher

___Credials___

___Bio___

Virginia “Ginny” Calega, MD, MBA, FACP

Vice President, Medical Management and Policy, Independence Blue Cross

Virginia “Ginny” Calega is Vice President, Medical Management and Policy, at Independence Blue Cross, where she is responsible for the ongoing analysis of utilization, medical cost, and health outcomes data, along with the development of interventions and programs to optimize these outcomes. She came to Independence after more than 13 years with Highmark, where she most recently served as Vice President of Strategic Clinical Solutions. She brings experience in care cost management, design, and implementation of strategic care cost initiatives.

She is board certified in internal medicine and geriatrics, is Past Chair of the Blue Cross Blue Shield Association Medical Policy panel, and received the Pittsburgh Business Times 2016 Healthcare Hero Award for work on the innovative Highmark Cancer Collaborative.

She completed her medical degree at the Medical College of Pennsylvania, her medical residency at Rhode Island Hospital, and her Master of Business Administration at Villanova University.

Nick Calla, RPh, Esq

Vice President, Industry Relations, Cardinal Health Specialty Solutions

President, Specialty Pharmacy Certification Board

Nick Calla is Vice President, Industry Relations, Cardinal Health Specialty Solutions, Pittsburgh, PA, and is responsible for the development of relationships in the manufacturer community as it pertains to products within their specialty portfolio. Prior to Cardinal Health, Nick was Vice President, Trade Relations, Community Specialty Pharmacy Network, where he was responsible for business development, relationship maintenance with manufacturers around the country, and the clinical programs designed to support those products. He also performed the same duties for Walgreens Specialty Pharmacy.

Prior to working at Walgreens, he was Director, Clinical Programs and Network Administration, Eckerd Health Services, and President and General Manager, Oncology Pathways, a group purchasing organization founded by the University of Pittsburgh Medical Center Hillman Cancer Center and Medmark Specialty Pharmacy. He has experience working with the pharmaceutical manufacturing and the retail pharmacy community and has also participated in several pharmacy and therapeutics committees.

He is a member of the National Association of Chain Drug Stores, Academy of Managed Care Pharmacy, and the National Association of Specialty Pharmacy. Currently, Nick is the President of the Specialty Pharmacy Certification Board. His expertise is in the areas of compliance, disease management, intervention programs, and negotiations.

He received his Bachelor’s degree in pharmacy from the University of Pittsburgh, PA, and received a Juris Doctorate from Duquesne University, Pittsburgh. In addition, he has completed fellowship programs at the University of Pennsylvania, Philadelphia; University of Southern California, Los Angeles; and Harvard University, Cambridge, MA.

Neil Canavan, MSc

Scientific Advisor, Solebury Trout

Neil Canavan is a veteran science journalist with more than 20 years of experience reporting on the technologies of drug development. He joined the Solebury Trout team as Scientific Advisor in 2014, where he recruits key opinion leaders in the immuno-oncology space to educate healthcare/biotechnology investors on this revolutionary, rapidly evolving field. After 2 years of organizing such symposia, it became clear that a wider educational effort was warranted. The culmination of that effort is Canavan’s new book, A Cure Within: Scientists Unleashing the Immune System to Kill Cancer.

Kevin Cast

Partner, Archbow Consulting

Kevin Cast is Partner, Archbow Consulting, Windermere, FL. His career in the pharmaceutical and biotech industries spans 3 decades. He has held sales and trade positions at Ciba-Geigy and Serono, and has managed specialty pharmacy accounts, distribution, and historically underutilized business development at Express Scripts as Vice President, Pharma Business Development.

Kevin enjoys leveraging this experience for Archbow clients by developing unique strategies to maximize the current supply/service chain, while considering trends that predict future needs.

He holds a Bachelor of Liberal Arts in biology from Illinois Wesleyan University, and a Master’s degree in botany from Oklahoma State University, Stillwater.

Once an EMT, he gets his money’s worth out of his botany degree by tinkering in his garden. He “botanizes at 65 miles per hour” on the long drives he and his wife of 30 years take to visit their 2 children. He’s proud that both of his kids have chosen careers in healthcare. His son is a PharmD, and his daughter is styding to become a speech pathologist.

Nicole Caswell, BBA

Executive Director of Operations, CoPilot Provider Support Services

Nicole Caswell is Executive Director of Operations, CoPilot Provider Support Services, Lake Success, NY, and has been a vital member of the CoPilot team for more than 7 years. CoPilot Provider Support Services is a healthcare information technology, call center, and HUB services company. Nicole is responsible for managing industry-leading, nationwide programs and dedicated teams who provide services such as medical and pharmacy benefits investigations, prescription fulfillment, reimbursement support, patient direct purchase, and patient assistance. Her scope of supervision includes subordinate staff encompassing 10 different roles, along with several supervisors and team leads.

Her focus is on ensuring that clients, such as pharmaceutical manufacturers and providers, across the country have access to innovative online solutions that allow them to provide better access to value-based care. The services overseen by Nicole include benefit verification, patient assistance, drug distribution, and reimbursement support.

She is extremely well-versed in this unique arena, having started from the ground up, beginning as a Program Support Specialist team member for 1 year, moving up to Team Lead for 1.5 years, and ultimately being promoted to her current Executive Director of Operations role. Since joining the company in 2011, she has demonstrated a commitment to excellence with strong leadership capabilities and advancing her career with CoPilot.

Nicole graduated with a Bachelor of Business Administration degree from Hofstra University, NY, in 2011, and continues to demonstrate her drive to further educate and support clients on effective utilization of the company’s unique services which ultimately increases speed to therapy for patients and eases administrative burdens for providers. She is also a Juris Doctor candidate at Seton Hall Law.

Bob Charles, BS, MBA

Principal & Founder, The GeneriSys Company

Bob Charles is a senior executive in the biotech distribution industry, with specific expertise in a payer-centric pharmacy model. Currently, Bob serves as Principal and Founder of GeneriSys, which is a global pharmaceutical channel manager with the mission to promote “Generics for America; Brands for the World.” Clients include Target, Humana, Prime Therapeutics, Fred’s Stores, PharMerica, Merck, Shire, and many others. In addition, he was Co-Founder and majority shareholder in Axon, a technology platform that connects physicians, payers, pharmacies, and other healthcare providers to automate the prior authorization transaction.

Previously, he was Staff Vice President at WellPoint Specialty Pharmacy, where he planned and implemented business development strategies that grew the start-up division to a more than $1 billion revenue base within 3 years.

Bob has worked in senior leadership positions at Priority Healthcare (Senior Director, Oncology Services), OptionCare (Vice President, Sales and Marketing), and Express Scripts Infusion and Specialty Services (Regional Director), consistently achieving improvements to clinical and financial outcomes.

In these roles, he has maintained deep relationships with pharmaceutical manufacturers, both brand and generic manufacturers. He serves on a variety of pharmaceutical ad boards, including Merck Bioventures, Biogen-Idec, Genzyme, GlaxoSmithKline, Genentech, Dr. Reddy Labs, and Aurobindo.

Finally, he serves on the Board of Directors for AOAExcel, a for-profit division of the American Optometry Association. In this role, he helped divest an information technology segment in a multimillion-dollar transaction. Continued work focuses on deploying value-added services for optometry practices, such as a group purchasing organization, HIPAA compliance, and practice transitions solutions.

Anthony Coletta, MD, MBA

___Credials___

___Bio___

Charlie Coltman

___Credials___

___Bio___

George William Daneker Jr, MD

Corporate Chief Medical Officer, Cancer Treatment Centers of America

George William Daneker Jr brings more than 30 years of surgical experience and clinical leadership in his position as Corporate Chief Medical Officer at Cancer Treatment Centers of America, where he helps to set the clinical culture for the enterprise and leads clinical program development, particularly around issues of clinical consistency and excellence in patient care. He is actively involved in the business transformation process, including the development of future business platforms.

His career in surgical oncology has included the care of patients with intra-abdominal cancers, skin and soft tissue cancers, and breast cancer. He is skilled at advanced procedures, such as laparoscopic surgery and robotics. He joined the Cancer Treatment Centers of America in 2011 as Clinical Lead in Atlanta, where his roles multiplied as Chief of Staff, Chief of Surgery, Chief of Nutritional Support, and Research Director.

Prior to his current role, he served as Chief of General Surgery, Director of Surgical Oncology, Oncology Research, and Robotic General Surgery at St. Joseph’s Hospital (now Emory Healthcare) in Atlanta. There, he initiated a research collaboration with the Georgia Institute of Technology and instituted the multidisciplinary tumor board for gastrointestinal oncology. He was Founding Partner of North Atlanta Surgical Association, a 20+ surgeon professional corporation, as well as a Founding Partner of CancerData.com and Vice President of Outpatient Surgical Management.

He has authored many journal articles, abstracts, and book chapters on cell biology, tumor biology, and surgical oncology. He co-edited The Mont Reid Handbook: The University of Cincinnati Surgical Manual, 2nd edition, in 1990 and has been a guest reviewer for The Annals of Surgical Oncology.

He has received numerous acknowledgments for his work, ranging from the Armand Hammer International Travel Award from the Society of Surgical Oncology, the Top Doctors for Cancer by Newsweek magazine since 2015, Top Cancer Doctors by Castle Connolly, and has been named by U.S. News & World Report in the top 1% of surgeons in the United States.

He graduated cum laude with a Bachelor degree in biology from Loyola College of Baltimore in Maryland, and earned a medical degree with honors at the University of Maryland School of Medicine in Baltimore. He completed his internship and residency in general surgery at the University of Cincinnati Medical Center, and completed his clinical and research fellowships at Harvard Medical School and The University of Texas M.D. Anderson Cancer Center.

Brian DeBusk, PhD, MBA

___Credials___

___Bio___

Michael DeLeo, MD

Chair, Division of Radiology, Foundation Medical Partners

Chair and Medical Director, Department of Radiology, Southern New Hampshire Medical Center Medical Director, diNicola Breast Health Center

Michael DeLeo currently serves as Chair of the Division of Radiology to the Board of Governors at Foundation Medical Partners, Chair and Medical Director of Radiology at Southern New Hampshire Medical Center, and Medical Director of the diNicola Breast Health Center in Nashua, NH. He serves on the Cancer Committee, Peer Review Committee, and co-chairs the Breast Program Leadership Team.

He is an Alpha Omega Alpha graduate of the University of Massachusetts Medical School. Following an internship in internal medicine at Massachusetts General Hospital, he completed a residency in diagnostic radiology and fellowship in women’s imaging at the Hospital of the University of Pennsylvania, where he also served as Chief Resident and completed a residency track in leadership and healthcare quality.

He is enrolled in the Master in Business Administration program at the Isenberg School of Management-University of Massachusetts, with a focus in medical management in partnership with the American Association for Physician Leadership. He enjoys time with his wife and 3 daughters.

Ravinder Dhawan, PhD

Vice President and Head, Oncology Product Line, Center for Observational and Real World Evidence, Merck

Ravinder Dhawan is Vice President and Head, Oncology Product Line, Center for Observational and Real World Evidence, at Merck, and has responsibility for generating evidence to support value proposition for Merck’s oncology products throughout their lifecycle. He has more than 20 years of experience in outcomes research, market access, and pharmaceutical pricing.

Prior to joining Merck, he served as Head of the Oncology Outcomes Group at Sanofi and was Head of Global Market Access in Oncology and Metabolics at Johnson & Johnson Pharmaceuticals for more than 10 years, and led the Outcomes Research Group at Roche prior to that.

Earlier in his career, he taught health economics at the University of Western Ontario in Canada and the University of Connecticut in the United States. During his career, he has developed wealth of experience in dealing with reimbursement and access issues with various health technology assessment agencies around the globe.

He has authored more than 70 abstracts, posters, and publications in health economics and outcomes research.

Atul Dhir, MD, DPhil

Chief Executive Officer, New Century Health

Atul Dhir is Chief Executive Officer of New Century Health. He is a physician and scientist with more than 25 years of leadership experience in building and leading innovative healthcare companies.

Before joining New Century Health, he was Chief Executive Officer of BiPar Sciences, a cancer-focused biotechnology subsidiary of Sanofi-Aventis. Prior to BiPar Sciences, he was at US Oncology (now McKesson Specialty Health), one of the largest providers of cancer care in the United States. During his time with US Oncology, he led several businesses, including serving as President of the company’s Cancer Research Group. He has also held senior positions in the healthcare division of Monsanto Company and as a consultant at McKinsey & Company.

He received his medical degree from the All India Institute of Medical Sciences in New Delhi, India. He completed his doctorate of philosophy in medicine from the University of Oxford, UK, where he studied as a Rhodes Scholar.

Luis Diaz, MD

Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center

Luis Diaz is the Division Head, Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center (MSKCC), where he specializes in the treatment of advanced pancreatic and colorectal cancers and directs the Precision Prevention & Interception Program. Prior to his role at MSKCC, he was a member of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins and directed the Swim Across America Lab. He is also founder of several entities that focus on genomic analyses of cancers, including Inostics, PapGene, and Personal Genome Diagnostics (PGDx).

He has undergraduate and medical degrees from the University of Michigan and completed residency training at the Osler Medical Service at Johns Hopkins and medical oncology training at the Sidney Kimmel Cancer Center at Johns Hopkins.

His pioneering work has involved the clinical development of tumor-derived DNA as a biomarker for cancer screening, early detection, monitoring, and measurement of early residual disease. The basis of this work is based on the well-accepted premise that cancer is defined by a discrete set of genetic alterations. This approach combines a next-generation genomic sequencing with novel digital techniques to count tumor-derived DNA fragments in complex mixtures of DNA. The mutations found in cancers are never found in normal cell populations and detection of these mutations therefore confers exquisite specificity to the assay. Accordingly, he demonstrated that the level of mutations in the circulation, also known as circulating tumor DNA (ctDNA), tracked with fluctuations in tumor burden in patients undergoing resective surgery for colorectal cancer. Most striking is the ability of ctDNA to accurately predict recurrence after surgery and monitor patients with undetectable CEA levels. This novel biomarker is based on personalized genomics that provides a “viral load” equivalent for patients with solid tumors. The preliminary studies served as the basis for his most recent invention, the “molecular pap smear,” which is a promising approach for the early detection of ovarian and endometrial cancers.

He has also harnessed the power of cancer mutations as potent antigens and championed the use of checkpoint inhibitors in the treatment of patients with tumors with high mutational burden. His landmark proof of this principle studies using PD-1 blockade in patients with mismatch repair deficiency and showing dramatic and potentially curative responses in more than 50% of metastatic patients, which resulted in the first historic FDA approval of a cancer treatment for any solid tumor in adults and children with a specific genetic feature.

He is a member of the groups that received the 2013 AACR Team Science Award for Pancreatic Cancer Sequencing, the 2014 AACR Team Science Award for Malignant Brain Tumor, and the 2017 AACR Team Science Award for Liquid Biopsies. He is also the leader of the 2017 SU2C Colon Cancer Dream Team. He is an elected member of the American Society for Clinical Investigation. In addition, his work has been highlighted in several scientific and lay media outlets, including The Diane Rehm Show, New York Times, NPR, CNN, and NBC nightly news.

Christian Downs, JD, MHA

___Credials___

___Bio___

Amy DuRoss, MBA

Co-Founder and Chief Executive Officer, Vineti

Amy DuRoss is Co-Founder and Chief Executive Officer of Vineti, which creates next-generation technology to drive and scale high-value medicine. Before co-founding Vineti, Amy was the Managing Director for GE Ventures, where she focused on GE Healthcare’s new business creation, Healthymagination. Prior to GE, Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was Co-Founder and Executive Director of Proposition 71, California’s $3-billion stem-cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency.

Amy holds a Masters in Business Administration and an MA/BA in English from Stanford University. She was named a 2016 Health Innovator Fellow by the Aspen Institute.

Richard Evans, DVM

Co-Founder and Head of Healthcare Practice, Sector & Sovereign Research

Richard Evans is Co-Founder and Head of Healthcare Practice of Sector & Sovereign Research Health. As a senior executive in the pharmaceuticals industry, his responsibilities ranged from corporate strategy to the pricing and distribution of the company’s products. Prior to founding SSR Health, he was the author of “Health and Capital,” which was published in August 2009. He was also a Senior Analyst at Sanford C. Bernstein and was ranked #1 by Bloomberg and Institutional Investor for his US pharmaceuticals coverage, and was ranked in the top 20 analysts worldwide. He was previously also Vice President, Business Policy and Account Management, at Roche.

He graduated in 1998 with his Doctor of Veterinary Medicine, specializing in large animals, food animals, and equine surgery, at the College of Veterinary Medicine, North Carolina State University. In 1991, he received his Masters of Public and Private Management from Yale University.

Matt Farber, MS

___Credials___

___Bio___

Brenton Fargnoli, MD

Senior Medical Director, Marketing & Strategy, Flatiron Health

Medical Director, Value-Based Care

Brenton Fargnoli is Senior Medical Director, Product Marketing & Strategy, and the Medical Director, Value-Based Care Flatiron Health. Brenton led the team that launched Flatiron’s Value-Based Care Initiative and scaled it across the country. He now focuses on the launch and growth of Flatiron’s provider-facing products and services. Brenton is board certified in Internal Medicine, and is also a practicing oncology hospitalist at Memorial Sloan Kettering Cancer Center.

Dr Fargnoli speaks frequently on the topic of value-based care, and his research has been published in international journals, including Cancer Research, and has been presented at the American Society of Clinical Oncology Annual Meetings. He previously worked in J.P Morgan’s Healthcare Investment Banking Group, and at Blue Cross Blue Shield of Rhode Island.

Dr Fargnoli completed his residency at Harvard’s Brigham and Women’s Hospital. He graduated summa cum laude from the University of Pennsylvania, earning his medical degree from the University of Pennsylvania School of Medicine, and his MBA in Healthcare Management from the Wharton School at the University of Pennsylvania.

A. Mark Fendrick, MD

___Credials___

___Bio___

Christine Ferro, CHFP

___Credials___

___Bio___

Anthony Fiori

Managing Director, Manatt Health

Anthony Fiori is Managing Director of Manatt Health in New York City. A recognized authority on health plan regulatory and financial issues, Anthony advises healthcare industry clients on regulations and strategy, analyzes policies, and manages projects. Medicaid and Medicaid managed care, the Affordable Care Act, healthcare financing, and delivery system reform are his areas of focus. He is also a recognized consultant on Federal Medicaid Pharmaceutical Policy.

He works with managed care organizations, hospitals, long-term care organizations, state Medicaid agencies, pharmaceutical manufacturers, and trade associations, bringing depth and perspective to public health insurance programs.

Currently, he leads a coalition of nonprofit Medicaid managed care plans in New York and represents these plans before the New York State Department of Health and other regulatory and legislative bodies on rate development, payment and delivery system reform, managed care expansion, health homes, and quality measurement. He also advises state hospitals and plans implementing the Affordable Care Act and Medicaid redesign—including the expansion of Medicaid managed care—in New York, Alabama, Oregon, North Carolina, and other states. In addition, he works for and advises pharmaceutical manufacturers on the implications of federal and state Medicaid policies with regard to their business.

Before joining Manatt, he worked for the New York City Economic Development Corp, where he structured debt for nonprofits, including a number of healthcare-related organizations. He also was a consultant to the Henry J. Kaiser Family Foundation, where he co-authored a report on the health insurance market and its impact on employer coverage.

As a policy advisor for the San Diego Regional Chamber of Commerce, he led a campaign to educate community and business leaders on the importance of a comprehensive and affordable healthcare network.

C. Lyn Fitzgerald

Senior Vice President, US & Global Development, National Comprehensive Cancer Network

C. Lyn Fitzgerald is Senior Vice President, US & Global Development, National Comprehensive Cancer Network (NCCN). In this role, she is charged with the development of US and International business strategies. She serves as the key contact for the industry and oversees the NCCN Corporate Council and all permissions and licensing of NCCN content for commercial use. In addition, she provides oversight of NCCN Business Development, NCCN Business Insights, NCCN International Program, NCCN Policy Program, NCCN Payer and Employer Outreach, NCCN Communications & Marketing functions, and the NCCN Academy for Excellence & Leadership in Oncology School of Pharmaceutical & Biotech Business.

Prior to joining NCCN, she was a member of the Business Development team at the Nemours/Alfred I. DuPont Hospital for Children, where she worked to develop and advance communication strategies for building and maintaining provider relationships. She was responsible for professional relations, including physician advocacy, and served as liaison to Nemours partner hospitals and to community practices, including providing educational programming and support.

From 1995 to 2001, she served as Key Specialty Senior Representative at Schering-Plough Pharmaceuticals. A 2-time Temple University graduate, earning a Bachelor of Business Administration in economics from the Fox School of Business and a Master of Journalism from the School of Communications. She is a published author of multiple articles on health and healthcare policy.

Mike Fitzgibbons, CFA

Founder and Chief Executive Officer, Claritas Rx

Mike Fitzgibbons has served as Chief Executive Officer of Claritas Rx since he founded the company in 2011. He is responsible for corporate management and leadership, strategic planning, and execution of the company’s business plan.

Prior to forming Claritas, he played a number of roles in marketing and market access at Genentech. He was previously Equity Research Analyst with Morgan Stanley, where he covered pharmaceutical services, drug distribution, and healthcare information technology. He holds the Chartered Financial Analyst designation and earned a bachelor’s degree at Amherst College.

William A. Flood Jr, MD

Chief Medical Officer, NantHealth

William A. Flood Jr is Chief Medical Officer at NantHealth, formerly Net.Orange, in Philadelphia, PA. Prior to his role, he was Associate Professor, Medicine, Penn State College of Medicine, and Assistant in Oncology at the Johns Hopkins Oncology Center.

Throughout his career, he has been the recipient of many awards, including numerous honor societies: Durack Award in Internal Medicine, DeLeo Prize in Oncology, and Zaslow Memorial Award at Temple University School of Medicine; and the American Society of Clinical Oncology Merit Award. He has also held many professional roles in different committees, including the Penn State/Hershey Medical Center Institutional Review Board, the Penn State Interdisciplinary Course Committee in Pulmonary Medicine, and the Penn State/Hershey Medical Center’s Technology Clinical Advisory Group. He has authored and co-authored many research studies, book chapters, and abstracts, and has been an invited speaker to the Centers for Medicare & Medicaid Services’ Oncology Care Model 2017 Optum Cancer Resource Services Expert Panel, the Huck Graduate Student Advisory Committee Career-Focused Seminar, and the National Comprehensive Cancer Network’s Academy for Excellence and Leadership in Oncology.

He received a Bachelor of Science degree in molecular and cell biology from The Pennsylvania State University, his medical degree from Temple University School of Medicine, and his Master of Science in health evaluation sciences from The Pennsylvania State University.

Elizabeth Franklin, LGSW, ACSW

Executive Director, Cancer Policy Institute, Cancer Support Community

Elizabeth Franklin is Executive Director, Cancer Policy Institute (CPI) at the Cancer Support Community (CSC). CSC is the largest provider of social and emotional support services for patients with cancer and their loved ones in the United States. The CPI brings together patient advocates and policy experts to ensure that the voices of patients with cancer and their loved ones play a central role in federal and state legislative, regulatory, and executive policymaking. The CPI works in partnership with patient advocates, the CSC affiliate network, and numerous allied healthcare and oncology organizations to work toward a future where 15.5 million cancer survivors have access to comprehensive, high-quality, timely, and affordable medical, social, and emotional care. Elizabeth is responsible for all aspects of the CPI, including legislative, regulatory, policy, and research priorities as well as operations, fundraising, and management. She was previously Senior Director of Policy and Advocacy at CSC.

Elizabeth was formerly Director of Policy and Engagement at The George Washington University Cancer Institute, where she worked at the macro level, developing and implementing the Institute’s policy agenda; and at the micro level, working with the patient-centered care team to ensure that all patients had access to high-quality, timely cancer care. Previously, she was Senior Director of Policy and Advocacy with the Prevent Cancer Foundation as well as Special Assistant to the Chief Executive Officer at the headquarters of the National Association of Social Workers.

She is a recognized author and speaker. Her articles have appeared in publications such as the Journal of Cancer Education, Health and Social Work, and CONQUER: the patient voice magazine. She has co-authored 2 books on nonprofit leadership and co-edited 2 social work texts. In addition, she is a member of various organizations and coalitions, including the National Association of Social Workers (where she serves as President of the DC Chapter), Association of Oncology Social Work (where she serves on the Advocacy Committee), Academy of Oncology Nurse & Patient Navigators (where she serves on the Leadership Council and as Chair of the Policy and Advocacy Committee), Alliance for Quality Psychosocial Cancer Care, and Society for Social Work and Research.

Currently a doctoral candidate at the University of Maryland School of Social Work, she is focusing her dissertation on the ways in which patients define value in the cancer care system and how those definitions can be incorporated into public policy and clinical practice. She obtained her Masters in social work from the University of Illinois at Chicago and her Bachelor’s degree in social work from the University of Kentucky. She is a Licensed Graduate Social Worker in the District of Columbia and a member of the Academy of Certified Social Workers.

Kimberly Freeman

Vice President, Commercial Strategy and Planning, Adaptimmune

Kimberly Freeman is Vice President, Commercial Strategy and Planning, Adaptimmune, a clinical stage biopharmaceutical company focused on development of T-cell receptor-based adoptive T-cell gene therapy to treat cancer. She joined Adaptimmune in 2016 to lead Global Commercial Strategy and Market Preparation for the successful development and launch of these novel therapeutics.

She has specialized in oncology for more than 25 years, working within the pharmaceutical industry in disciplines across research, clinical development, new product planning, marketing, market access, and sales. Previously, she served as Head of Oncology National Accounts at Boehringer Ingelheim Pharmaceuticals, where she launched their first oncology product and companion diagnostic. Prior to that, she spent 17 years at GlaxoSmithKline, where she launched 5 unique oncology products, including treatments for solid tumors and hematologic malignancies, as well as supportive care agents. During her tenure at GlaxoSmithKline, she developed an expertise with respect to oral oncology therapies and the access, distribution, and reimbursement of these products.

She holds a Masters degree in biology from Cornell University.

Rowdy Gaines

Speaker, Swim Across America

Vice President, Aquatics, Central Florida YMCA

Throughout the 1980s, Rowdy Gaines was the fastest swimmer on the planet, and his world records confirmed his place in swimming history when he set world records in the 100- and 200-meter freestyles at the Olympic Games in Moscow, Russia. He has been induced into the US Olympic Hall of Fame and the International Swimming Hall of Fame.

In 1991, he was diagnosed with Guillain-Barre syndrome, an autoimmune virus that attacks the nervous system, and he was paralyzed for more than 2 weeks. He fought back, overcame the disease, and 1 year later went to the World Masters Championships and won the 50- and 100-meter freestyle events.

He works with many charitable organizations, including the USA Swimming Foundation; Swim Across America, which benefits research for cancer; and the Special Olympics. He mentors kids and spreads the message that championship comes not from the outside, but from the inside, and dreams can come true if you believe in yourself. He is a highly sought after motivational speaker and shares his inspiring story of perseverance.

Jude Gallagher

Founder and Managing Partner, Channel Health Advisors

Jude Gallagher is a strategic leader with more than 30 years of healthcare experience across a spectrum of provider and payer systems. She is Founder and Managing Partner of Channel Health Advisors in Louisville, KY. As a Certified Physician Assistant with a Master’s in Business Administration, her expertise and leadership within direct patient care, program design, hospital administration, and managed care produced novel clinical strategy and program designs, quality and operational improvements, resulting in moving complex problems to operational success.

In her previous role as Director, Complex Care Clinical Strategy, at Humana, Jude designed and implemented a broad range of programming, including direct-to-consumer self-management programs and provider-facing quality and value-based designs. She participated in “buy versus build” decision- making as well as vendor partner selection and implementation of national programs. She led advanced care planning strategy and introduced intervention designs based on stages of health, from the very well to seriously ill adult. Before working at Humana, she was Vice President, Clinical Operations, Quality Oncology, where she provided strategic oversight and direction of the Utilization Management, Care Management, and Quality Programs. This included leading implementation of 50 contractual relationships with national and regionally based payers and employer groups.

Jude brings her passion for supporting each individual’s voice in healthcare decision-making and improving navigability of care delivery. She shares her talents through mentoring of others and serving on the boards of local cancer nonprofits.

Lisa Gill, CPA

Managing Director, Senior Analyst, US Healthcare Technology and Distribution Equity Research, J.P. Morgan

Lisa Gill is Managing Director and Head of US Healthcare Technology and Distribution Equity Research for JP Morgan in New York City for 16 years. She has been a member of the highly regarded JP Morgan Healthcare research team for 20 years, has been ranked #1 by Institutional Investor for the past 8 years, and has consistently been ranked in the top 3 by Institutional Investor and external polls since 2005. In her current position, she is responsible for coverage of 17 companies within healthcare services, including healthcare distribution, pharmacy benefit management, drug retail, healthcare information technology, clinical labs, and institutional pharmacy sectors.

She is a certified public accountant and started her career with Ernst & Young’s audit group, specializing in healthcare facilities. She then worked at Coopers & Lybrand’s healthcare services consulting group, where her main focus was on physician and long-term care reimbursement. Prior to joining JP Morgan, she was Director of Development at Health Partners, where she acquired physician practices in New York City.

She is currently a member of the Investment Bank Women’s Network and a leading member on the Mentoring Committee of Women in Research.

Ilya Gipp, MD, PhD

Oncology Executive, Philips HealthTech

Ilya Gipp is Oncology Executive representing Philips HealthTech for the oncology products portfolio in Southeastern United States since 2017. He relocated from the Netherlands, where he was responsible for Magnetic Resonance (MR) Therapy and Radiation Oncology Solutions business development of Royal Philips globally.

Prior to joining Philips in 2005, he has worked as a radiologist and later as a head of Russia’s largest radiology department in Gazprom Clinic, Moscow. He has driven the conversion to first-in-the-country filmless radiology department and has organized the first full-scale picture archiving and communication system. He has managed numerous partnerships between the clinic and various industrial companies for co-developing new technologies, medical environment testing, and ensuring legal compliance for developed products with state legislation.

His major interest has always been MR imaging, and in his multiple roles at Philips, he has primarily stayed linked to the MRI product line. He manages MR/CT businesses in Europe and Central Asia; field marketing for MR in Europe, the Middle East, and Africa; and he heads the business development team for radiation therapy and MR simulation within the global Radiation Oncology Solutions team.

He has more than 40 scientific papers in peer-reviewed journals related to various areas of diagnostic imaging, management in radiology, and healthcare informatics.

He received his medical degree in diagnostic radiology and his Doctor of Philosophy degree in neuroradiology. He currently resides in Atlanta, GA, with his wife and 2 sons.

Robert Goldberg, PhD

Co-Founder and Vice President, Center for Medicine in the Public Interest

Robert Goldberg is Co-Founder and Vice President of the Center for Medicine in the Public Interest (CPMI), a nonprofit organization that advocates for consumer access to medical innovation, better health information, and personalized healthcare. He is also Founder of CMPI’s Value of Medical Innovation initiative that promotes awareness of the value of medical progress.

Prior to founding CMPI, he was Director of the Manhattan Institute’s Center for Medical Progress and Chairman of its 21st Century FDA Task Force that examined the impact of the FDA’s Critical Path Initiative on drug development and personalized medicine.

His academic research focuses on the value of personalized medicine and medical innovation to longevity, economic growth, and well-being. He is the author of Tabloid Medicine: How the Internet Is Being Used to Hijack Medical Science for Fear and Profit (Kaplan, 2011), and writes op-eds and articles for a wide variety of media outlets, including Scientific American.

Patricia Goldsmith

Chief Executive Officer, CancerCare

Patricia Goldsmith is Chief Executive Officer of CancerCare since 2014, overseeing the vision and direction of the organization. Patricia brings more than 20 years of nonprofit management and strategic planning experience to the role, and has a proven record of success in hospital and physician academic organizations, as well as nongovernmental healthcare organizations.

She previously served as Executive Vice President and Chief Operating Officer at the National Comprehensive Cancer Network (NCCN). In this role, she was responsible for the overall operations of the NCCN. She reported directly to the Chief Executive Officer and provided oversight of the functions of the NCCN Oncology Outcomes Database, NCCN Oncology Research Program, Finance, US & Global Business Development, Marketing and Communications, Public Affairs, Professional Publications, Best Practices, Analytics, Research & Consulting, Conferences and Meeting Planning, Media Programs, Continuing Medical Education, Grants, and Information Technology. In addition, she was responsible for public policy initiatives at the federal level and national initiatives related to payers and employers, including the education related to these constituencies. Patricia was also responsible for the NCCN Foundation, established as the philanthropic affiliate of NCCN to embrace the NCCN mission of improving the quality and effectiveness of care provided to patients with cancer.

She formerly served as Vice President for Institutional Development, Public Affairs, and Marketing at the Moffitt Cancer Center in Tampa, FL, a NCCN Member Institution. There, she oversaw the Moffitt Cancer Center’s Foundation, Public Relations, Marketing, and Business Development functions in addition to fundraising initiatives. Before joining Moffitt, she developed and directed all managed care activities for the University of South Florida College of Medicine.

A frequent speaker at national meetings and symposia, she was chosen by US Representative Bill McCollum (R-FL) in 2003 to join a panel of 100 thought leaders representing every stakeholder interest in healthcare. This unique effort focused on building consensus about what structural changes could be made in our nation’s healthcare delivery system to assure quality healthcare for future generations. Recently, she participated as a faculty panel member at Bristol-Myers Squibb’s 2015 Market Access Summit, focusing on the patient experience from diagnosis, through treatment, and beyond, and at the Fifth Annual Association for Value-Based Cancer Care Conference, where her session focused on patient engagement and patient assistance. Prior to these conferences, she participated as a speaker at the 16th Annual Patient Assistance & Access Programs Meeting, her session, entitled “Cross-Functional Strategies for Advocacy Relationship Development,” and as a panel participant at the Turning the Tide Against Cancer Through Sustained Medical Innovation Conference, her session, entitled “Addressing the Value and Cost of Cancer Care.”

She has studied at the Pennsylvania State University, the University of Missouri Bloch School of Business, and the Harvard School of Public Health. She was a winner of the 1999 Distinguished Women in Business Award sponsored by the Business Journal of Tampa Bay and also was named the 1999 Leukemia Society Woman of the Year, an award based on her philanthropic efforts on behalf of The Leukemia Society.

Bruce Gould, MD

President and Medical Director, Northwest Georgia Oncology Centers

Bruce Gould is currently President and Medical Director of Northwest Georgia Oncology Centers (NGOC). During his recent presidency of Community Oncology Alliance (COA), he led the organization through a period of rapid growth, financial stability, and far-reaching initiatives that have had a lasting impact on community oncology. Examples include ground-breaking studies documenting the shift in the site of care, cost drivers in cancer care, and growth and costs of the 340B Drug Discount Program. Under his leadership, COA played a major role in stopping the Center for Medicare & Medicaid Innovation (CMMI) initiative, the “Part B model.”

Since January 1990, he has been involved in direct patient care at NGOC, which has kept him grounded in the special needs and challenges of caring for patients with cancer. This has led to him being an early champion of the Oncology Medical Home (OMH). In 2011, he was appointed Chairman of COA’s OMH Steering Committee, which served to refine the model with input from patients, payers, and other providers. This work helped lead to the launch of the Centers for Medicare & Medicaid Services’ Oncology Care Model. Under his leadership, he guided NGOC through several other payer projects, including the UnitedHealthcare’s Episode of Care pilot and the CMMI’s COME HOME project; NGOC was instrumental in contributing to these projects’ successes.

Prior to his service at NGOC, he completed a Fellowship in Cancer Medicine at Duke University.

Lance Grady

Vice President and Team Lead, Market Access and Reimbursement, Avalere Health

Lance Grady is Vice President and Team Lead of Market Access and Reimbursement at Avalere Health, where he devises commercialization strategies focused on value, access, and reimbursement. With a focus on oncology and more than 20 years of experience in policy, access, reimbursement strategy, and execution, he is passionate about providing practical and meaningful point-of-care solutions that are viable to all healthcare stakeholders. Lance delivers proven, measurable outcomes by designing integrative and sustainable answers to complex issues in functional areas pertaining to patient access strategy and services; physician-administered reimbursement strategy and support; value-based and risk-based payment models; US Department of Health and Human Services’ policy strategy; alternative payment models; net pricing strategies and value-based arrangements; commercial health plan formulary, medical policy, and utilization management; benefit design; drug-dollar-data flow; oncology pathways; and specialty channel strategies.

Prior to joining Avalere Health, he enjoyed a successful 12-year career at Bristol-Myers Squibb in various leadership roles in US Market Access. He also has experience in orphan drug and autoimmune therapeutic markets. He is a graduate of the University of Louisiana-Monroe, where he studied human biology and immunobiology.

Robert Green, MD

Senior Vice President, Clinical Oncology, Flatiron Health

Robert Green is the Senior Vice President, Clinical Oncology, Flatiron Health, New York, NY, and practicing medical oncologist. In his role as Senior Vice President, he oversees the team responsible for clinical development of OncoEMR, the industry’s leading electronic medical record software for medical oncology, as well as Flatiron’s other provider-facing software products, and clinical content development.

Prior to joining Flatiron Health, he was Managing Partner, Palm Beach Cancer Institute, FL, and helped lead its merger with Florida Cancer Specialists in 2013. He continues to see patients in West Palm Beach, FL, at Florida Cancer Specialists on a part-time basis. Previous to that, he served as Chief Medical Officer at Cancer Clinics of Excellence, where he led initiatives on molecularly based clinical trials, integrating genomic testing into community practices, alternative payment models, and data analytics. He currently serves on the board of the Community Oncology Alliance.

He received his undergraduate and medical degrees from Duke University and a Master’s of Science degree in clinical epidemiology and biostatistics from the University of Pennsylvania.

Lindsay Bealor Greenleaf, JD, MBA

Director, ADVI Health

Lindsay Bealor Greenleaf is Director at ADVI Health, where she leads ADVI’s public policy activities and provides strategic counsel on legislative and regulatory issues pertaining to Medicare, Medicaid, and the commercial market, as well as prescription drug coverage and reimbursement, provider reimbursement across sites of service, consumer-driven health plans, and commercialization of digital health products.

Lindsay has an extensive background in leveraging quantitative analysis to bolster clients’ value proposition, as well as experience with scoring the cost implications of policy proposals. In addition, she serves as Company Spokesperson and leads ADVI’s media relations strategies.

Before joining ADVI, she spent 6 years with The McManus Group, where she developed and negotiated legislative solutions with stakeholders, congressional staff, and members of Congress on behalf of clients spanning the pharmaceutical, biotechnology, and medical device industries, physician societies, and employee benefit administrators.

She is licensed to practice law in Texas and the District of Columbia. She earned a Juris Doctorate from the University of Houston Law Center, a Master of Business Administration from the Bauer College of Business, and a Bachelor of Arts in government from the University of Texas at Austin.

Melinda Haren, RN

Senior Director, Access Strategies, Zitter Health Insights

Melinda Haren joined Zitter Health Insights in 2004 and is currently Senior Director, Access Strategies. She has been part of the development of the majority of Zitter Health Insights’ syndicated product lines. Melinda is an acknowledged expert in prior authorization and payer coverage strategy. Her current role is in helping our clients understand the payer market and how it may impact their strategies. She has authored one book and scores of articles on healthcare and speaks frequently at national meetings.

Prior to Zitter Health Insights, she worked as Disease Manager at Highmark, where she designed and implemented a disease management program for approximately 20,000 members. The program increased member satisfaction and decreased the opt-out rate to less than 1% and saved more than $80,000 a year. The program was recognized by the National Committee for Quality Assurance in its 2002 Quality Compass.

She earned her registered nurse license from Harrisburg Area Community College and her Bachelor of Arts from Thomas Edison College of New Jersey.

Lisa Harrison, RPh

Vice President, Practice Business Solutions, Specialty Physician Services, AmerisourceBergen

Lisa Harrison is Vice President, Practice Business Solutions for AmerisourceBergen’s Specialty Physician Services. She oversees solutions to enhance business performance for community practices and empower patient care in her current role. Lisa also leads the Specialty Oncology Network advisory panel for the organization. Members of the panel include pharmacy directors, physicians, and administrators.

Lisa was formerly the Director of Pharmacy Services for ION Solutions, an AmerisourceBergen company, where she led the Clinical Practice Consultant team. In this role, she and the Clinical Practice Consultant team supported the development and implementation of the Specialty Oncology Network Physician Dispensing and Retail Pharmacy clients. She brings 12 years of experience in oncology, with 8 years spent in a large oncology practice and 4 additional years on the provider side of the industry.

She earned her Bachelor of Science in chemistry and business from Judson College followed by a Bachelor of Science in pharmacy from Auburn University.

Edward Hensley

Founder and Chief Commercial Officer, AssistRx

In 2010, Edward Hensley founded AssistRx, a technology-enabled pharmaceutical solutions company that focuses on creating digital solutions for patients prescribed specialty medications. He is also on the Board of Directors for etectRx and the United Arts of Central Florida. He has spent his entire career in healthcare, focused mainly in the specialty segment.

He was part of the original management team at CuraScript, serving as Vice President of Pharmaceutical Relations. After successfully transitioning his role after the Express Scripts transaction in 2004, he went on to establish Advanced Care Scripts in fall 2005. After experiencing explosive growth when the Medicare Part D benefit was introduced, in late 2008 he sold and transitioned the business to Omnicare, which is now part of CVS Health.

He holds a Bachelor of Arts degree in English from The University of Texas at Austin and a Master’s in Business Administration from The Jones School of Business at Rice University.

Tara Herington

Vice President, Sonexus Access and Patient Support, Cardinal Health Specialty Solutions

Tara Herington is Vice President, Sonexus Access and Patient Support, Cardinal Health Specialty Solutions, where she leads her team to provide solutions beyond traditional HUB services to help patients and providers access specialty products with unprecedented speed, efficiency, and empathy.

Tara is a seasoned biotechnology and operations executive with more than 20 years of experience, and has successfully built organizations and programs for small, mid-sized, and large pharmaceutical manufacturers. She enjoys working in concert with manufacturers to deliver outstanding patient support programs that deliver patient-centered results.

Prior to her current role with Cardinal Health, she was responsible for leading patient support programs for pharmaceutical companies ranging from orphan disease medications to blockbuster products. She also has experience in field reimbursement, training, payer strategy, and quality assurance. She maintains her registered nurse licensure in the state of Texas.

Jennifer Hinkel, MSc

Partner, McGivney Global Advisors

Jennifer Hinkel is Partner at McGivney Global Advisors, where she leads initiatives in areas including economic impact analysis, market research, managed care and payer marketing, organized customer marketing, pricing and contracting, distribution strategy, and digital health.

Prior to joining McGivney Global Advisors, she was part of Genentech’s Industry Analytics group, where she led financial impact assessments of health policy, Medicare reimbursement, and policy-related industry trends. She is a graduate of Roche and Genentech’s accelerated Global Management Program, during which she held roles in pricing, contracting, and distribution strategy for North America, oncology marketing for Argentina, hospital sales and account management for the United Kingdom, and specialty therapeutics marketing for the United States. Prior to her time at Roche, she was Manager at the National Comprehensive Cancer Network, working on cancer center best practices and optimizing safety and efficiency in hospitals and the cancer care delivery system.

She has also been Partner and Founder in a mobile healthcare technology startup, Lecturer in Health Systems and Health Economics at Penn State University and Arcadia University, and has health policy experience in Washington, DC, and as a United Kingdom Parliament Staffer.

She holds a Master of Science degree from the London School of Economics, where she studied international health policy, health economics, and pharmaceutical economics. She is currently working toward a Doctor of Philosophy degree in evidence-based healthcare at the University of Oxford in conjunction with Oxford’s Centre for Evidence Based Medicine.

Axel Hoos, MD, PhD

Senior Vice President, Oncology Research & Development, GlaxoSmithKline

Axel Hoos is Senior Vice President, Oncology Research & Development, at GlaxoSmithKline Pharmaceuticals (GSK). As leader of oncology, he oversees its discovery and development functions and builds the oncology portfolio of GSK across several modalities, including antibodies, small molecules, bispecific molecules, and cell and gene therapies. The scientific focus is on immuno-oncology, epigenetics, and cell therapy. He also serves on the Scientific Advisory Board of the HIV Cure Center, a co-venture of GSK and the University of North Carolina at Chapel Hill.

He further serves as Executive Chairman of the Board of Trustees of the Sabin Vaccine Institute, a global health organization; Non-Executive Director on the Board of Imugene, a biotechnology company; Co-Chairman of the Cancer Immunotherapy Consortium; Scientific Advisory Board Member of the Cancer Research Institute; Scientific Advisory Group member at the Parker Institute for Cancer Immunotherapy; and Industry Co-Chair of the Partnership for Acceleration Cancer Therapies of the US Cancer Moonshot.

His efforts in medicines development and global health focus on novel and transformational therapies for life-threatening diseases, scientific and procedural innovation, and broad collaboration across multiple constituents to solve complex health problems. Through his leadership, a new paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of immuno-oncology.

Previously, he was Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb, where he developed Yervoy (ipilimumab), the first life-extending therapy in immuno-oncology. Before Bristol-Myers Squibb, he was Senior Director of Clinical Development at Agenus Bio (previously Antigenics), a biotechnology company.

He holds a medical degree from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center, both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich, Germany, and further in surgery, molecular pathology, and tumor immunology at Memorial Sloan Kettering Cancer Center in New York, NY. He is an alumnus of the Program for Leadership Development at Harvard Business School.

Clifford Hudis, MD, FACP, FASCO

Chief Executive Officer, Conquer Cancer Foundation and the American Society of Clinical Oncology

Chairman, Board of Governors, CancerLinQ

Clifford Hudis is Chief Executive Officer of the American Society of Clinical Oncology (ASCO), Chief Executive Officer of ASCO’s Conquer Cancer Foundation, and Chairman of the Board of Governors of ASCO’s CancerLinQ. He previously served in a variety of roles at ASCO, including President during ASCO’s 50th anniversary year (2013-2014). Before transitioning full-time to ASCO, he was Chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center in New York City, where he was also Professor of Medicine at the Weill Medical College of Cornell University. In this role, he developed more effective treatments for all stages of breast cancer, while also exploring novel prevention opportunities.

As Chief Executive Officer of ASCO, his focus is on education, research, and promotion of the highest quality of care by the Society’s nearly 45,000 members. Key initiatives include the acceleration of CancerLinQ, ASCO’s focused effort to increase insights, and learning from the rapidly accumulating electronic records of routine care provided by clinicians.

Jonny Imerman

___Credials___

___Bio___

Louis Jacques, MD

Chief Clinical Officer, ADVI Health LLC

Louis Jacques is Chief Clinical Officer at ADVI Health LLC, a healthcare advisory services firm, where he is also a partner. He leads preclinical and clinical development work on postmarket coverage. He has a distinguished career in government service and medicine, which includes his experience as Director of Coverage & Analysis and Division Director of Items and Devices for the Centers for Medicare & Medicaid Services (CMS), where he led the collaboration with the US Food and Drug Administration in the Entrepreneurs in Residence Program.

While working for CMS, he managed the Medicare Fee-for-Service Coverage Policy development on technologies as diverse as molecular diagnostic testing, implanted cardiac devices, advanced imaging, chemotherapeutics, wound care, and screening and preventive services.

Before joining CMS in 2003, he served as Associate Dean for Curriculum at Georgetown University School of Medicine, where he also saw patients at the Lombardi Cancer Center in his practice of hospice and palliative medicine. He is passionate about change and innovation and has coauthored more than 60 Medicare Coverage Determinations and developed program oversight of the Local Coverage Determination process.

Paul Jardina, MBA

President and Chief Executive Officer, Onco360® Oncology Pharmacy Solutions

Paul Jardina is President and Chief Executive Officer of Onco360 Oncology Pharmacy Solutions, where his overall responsibility is the strategic direction of the company and execution of its plans. He has led the continued development of the company’s clinical pharmacy services focused on providing evidence-based, high-touch services to patients and oncologists in the community-based, academic medical center, and hospital setting. Paul has more than 23 years of experience in the healthcare industry, with the majority of that time dedicated to oncology.

Prior to joining Onco360, he served as President and Chief Executive Officer of U.S. Physiatry, a physician services company focused on transitional care in the post-acute continuum. Over the course of the previous 10 years, he served in various leadership positions for US Oncology (now part of McKesson Specialty Health), including leading the oncology specialty pharmacy, drug distribution, radiation and imaging, and other business lines for the company.

He holds a Bachelor of Science in industrial engineering from Georgia Tech and a Master in Business Administration from Emory University.

Danelle Johnston, MSN, RN, ONN-CG, OCN

Chief Nursing Officer and Senior Director of Strategic Planning and Initiatives, The Lynx Group

Danelle Johnston is Chief Nursing Officer and Senior Director of Strategic Planning and Initiatives for The Lynx Group. In this role, she oversees the strategic and operational responsibilities of staff, programs, and expansion of the Academy of Oncology Nurse & Patient Navigators (AONN+) as well as the execution of its mission. She is instrumental in supporting the many committee activities within AONN+, exploring and nurturing partnerships with other organizations in clinical and oncology arenas, and providing key clinical and professional insight that will help AONN+ enhance its sponsorships and services.

With more than 24 years of experience holding a variety of positions and a diverse and progressive oncology nursing background, Danelle is recognized as a national leader in oncology nurse navigation and in innovative community outreach and education focused on improving clinical care coordination and supporting the growth of others in the profession. Providing the most recent evidence of this was her appointment to the Biden Cancer Initiative Advisory Committee.

As a longtime AONN+ member, Danelle serves on the Academy’s Leadership Council and is Co-Chair of its Quality Metrics Task Force. Her leadership has helped the task force to identify and document 35 standardized evidence-based metrics for navigation that concentrate on return on investment, patient experience, and clinical outcomes. For her efforts, AONN+ recognized Danelle with its “Exceptional Research in Navigation Award.”

She earned a Bachelors from Azusa Pacific University and a Masters in nursing, with an emphasis on leadership and management, from Western Governors University. She is a member of the American Cancer Society’s National Navigation Roundtable: Evidence-Based Promising Practices Committee.

Anna Kaltenboeck

Program Director and Senior Health Economist, Center for Health Policy & Outcomes, Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center

Anna Kaltenboeck is Program Director and Senior Health Economist at the Center for Health Policy & Outcomes, Department of Epidemiology & Biostatistics, at Memorial Sloan Kettering Cancer Center, where she focuses on the development of value-based drug pricing, methods, and policies to foster rational and sustainable drug prices.

Prior to joining Memorial Sloan Kettering Cancer Center, she spent 10 years consulting on health economics and outcomes research, as well as pricing and market access for pharmaceutical and diagnostic products. An alumna of both Analysis Group and IMS Consulting Group, the scope of her work spans the United States, the European 5, and emerging economies. She has published numerous articles in peer-reviewed scientific and policy journals.

She holds Bachelor’s and a Master’s degrees in economics from Tufts University.

John Kelton, PharmD

US Medical Director, Biosimilars Inflammation, Pfizer

John Kelton is US Medical Director, Biosimilars Inflammation for Pfizer and has more than 25 years of experience in the pharmaceutical industry. Since 2000, John’s focus has been on medical affairs, serving in a variety of capacities, including management of medical communications and training, medical review, medical education, medical science liaisons, and investigator-initiated trials.

For the past 5 years, John has been actively involved in biosimilar development and educational efforts in the United States and Europe. He has collaborated with biosimilars experts who have expertise ranging from bench to bedside in nephrology, inflammation, and oncology in order to capture and communicate the unique aspects of biosimilars and their development programs.

Prior to his roles in medical affairs, he functioned as Regional Pharmacy Manager for Abbott, where he managed pharmacy operations for parenteral and nutritional products as well as key clinical relationships with major healthcare systems.

He received his Doctor of Pharmacy from the University of Southern California. Before joining industry, John practiced as a clinical pharmacist, specializing in parenteral nutrition and oncology.

Daniel Klein

President and Chief Executive Officer, Patient Access Network Foundation

Dan Klein brings more than 35 years of executive leadership in healthcare and information technology services to the Patient Access Network (PAN) Foundation. His mission at PAN is twofold—to help seriously ill people get access to the care they need by providing grants to pay for their deductibles, copayments, and coinsurance; and to advocate for more systemic and sustainable ways to reduce out-of-pocket costs and make treatment more affordable for people with life-threatening, chronic, and rare diseases by lowering out-of-pocket costs.

Since joining the PAN Foundation in 2014, he has expanded PAN’s capacity to help the growing number of patients who need financial assistance, strengthened PAN’s compliance program to ensure that PAN continues to fulfill its mission in strict compliance with regulations, and implemented new technology to enhance the patient experience and to better support the needs of healthcare providers and pharmacists.

He previously served as Senior Vice President for the Cystic Fibrosis (CF) Services Specialty Pharmacy and then as Senior Vice President for Patient Access Programs at the CF Foundation. His leadership at the CF Foundation led to the steady growth and eventual sale of the CF Services pharmacy to Walgreens. He also launched the CF Patient Assistance Foundation, which provided financial assistance and case management services to underinsured patients living with cystic fibrosis.

In addition to his leadership in patient assistance, he has served as Chairman and Chief Executive Officer of Panurgy Corporation, a leading mid-market information technology services company, and as a consultant on health promotion and health planning to the US Department of Health and Human Services and the Pan American Health Organization, respectively.

Ira Klein, MD, MBA, FACP

Senior Director, Healthcare Quality Strategy, Strategic Customer Group, Johnson & Johnson Health Care Services

Ira Klein is Senior Director of Healthcare Quality Strategy in the Strategic Customer Group of Johnson & Johnson Health Care Services, advancing Janssen’s ability to deliver industry-leading value-based solutions to the new value-based marketplace. Key areas of focus in this role include building the business case for the Institute for Healthcare Improvement’s Triple Aim Solutions, delivering high value collaborations with ecosystem partners in the integrated delivery network, accountable care organizations, payer, and pharmacy benefit managers, and Janssen brand commercial strategy. This work is facilitated by a personal record of having worked on a variety of national quality and policy committees in Washington, DC, and with many medical specialty societies and patient advocacy groups. Previously, he was National Medical Director, Clinical Thought Leadership, Aetna, capping a 10-year career in the national payer space. During this time, he founded the Oncology Solutions team, creating and administering value-based and medical home contracts in oncology. In addition, during his time at Aetna he oversaw advanced analytics in population health and novel benefit designs for large self-insured employers, and developed wellness and chronic care programs that innovated in value-based care and behavioral motivational theory.

Prior to Aetna, he led the quality, cost, and care management area for the Bayshore Community Health System, including inpatient, outpatient, subacute, and long-term care services. This included oversight of all utilization management, JCAHO credentialing, CMS quality programs, and medical staff management. Prior to that, he was Chief Medical Officer of Elderplan, a CMS-enacted Medicare Demonstration Project in New York City serving the frail elderly. In this role, he reorganized a pharmacy benefit structure for Medicare-eligible members (5 years prior to CMS Part D), created coordinated care programs for multiple morbidities, and led quality and clinical reporting to governmental agencies. He began his career practicing internal medicine for 7 years at Robert Wood Johnson Medical School as Assistant Professor in the Division of General Internal Medicine.

He holds a Bachelor of Science degree from Rutgers, The State University of New Jersey, College of Pharmacy, a medical degree from the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, and a Masters in Business Administration from Rutgers University, graduating with honors from all 3 programs. He has a personal interest in health information technology and data security, previously certified in the medical health information technology area.

Chrys Kokino

___Credials___

___Bio___

Michael Kolodziej, MD

Vice President and Chief Innovation Officer, ADVI Health

Michael Kolodziej is Vice President and Chief Innovation Officer, ADVI Health. He attended college and medical school at Washington University in St. Louis, where he was Phi Beta Kappa and Alpha Omega Alpha. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia. After completing training, he joined the faculty at the University of Oklahoma School of Medicine, where he was Associate Professor. He joined New York Oncology in winter 1998, and was a Partner in the practice until December 2012.

He was an active member of the US Oncology Pharmacy and Therapeutics Committee, on the Executive Committee from 2002-2011, and Chairman from 2004-2011. He served as Medical Director, Oncology Services, for US Oncology from 2007-2011. In this role, he helped direct the implementation of the US Oncology Clinical Pathways Initiative, the integration of the US Oncology electronic medical record into this program, and the development of the US Oncology Disease Management and Advanced Care Planning programs, now known as Innovent Oncology. He joined Aetna in January 2013, as National Medical Director, Oncology Solutions. While at Aetna, he directed Aetna’s Oncology Delivery Reform pilots and was the architect of the Aetna Oncology Medical Home program. He was also active in Aetna’s Pharmacy Policy, Condition Analysis, and Genetics subcommittees. He joined Flatiron Health in July 2016, as National Medical Director, Managed Care Strategy, where he applied the core tech and data capabilities of Flatiron to facilitate practice transformation and success in alternative payment models. He joined ADVI in October 2017.

He is a Fellow of the American College of Physicians. He has published and spoken extensively on payment reform, personalized medicine, and practice care delivery transformation in oncology.

Crystal Kuntz

Vice President, Healthcare Policy & Research, Biotechnology Innovation Organization (BIO)

Crystal Kuntz is Vice President for Healthcare Policy and Research at the Biotechnology Innovation Organization (BIO), where she directs the association’s policy efforts related to Medicare, Medicaid, health reform, and economic trends and policies impacting BIO member companies.

Prior to BIO, Crystal was Vice President for Policy and Regulatory Affairs at America’s Health Insurance Plans, where she focused on policy and regulatory issues related to the implementation of the Affordable Care Act as well as prescription drug policy. Previously, she served as Senior Director for Policy at Coventry with a focus on Medicare as well as the implementation of healthcare reform. In addition, she served in senior policy roles at 2 pharmaceutical companies—Astellas Pharma US and Novartis. Before moving to the private sector, she led legislative and policy efforts related to the Medicare Advantage program and Part D within the Office of Legislation at the Centers for Medicare & Medicaid Services. There, she was part of the team that worked on the passage of the Medicare prescription drug benefits in 2003 and its early implementation.

She received her undergraduate degree in government and international affairs from Augustana College and has a Masters in public administration from Syracuse.

Rick Lee, MHA

Executive Chairman, CancerLife

Director, M3 Information

Rick Lee has made a career in the creation and sales of specialty healthcare applications and services sold to employers and health plans. He is currently Executive Chairman of CancerLife and Director of M3 Information. He was one of the early architects of the managed mental health (1982) and disease management (1994) industries. Since 2006, he has been toiling in the behavioral change vertical, first as President of Magellan’s Employee Assistance Program Division; then as Founder and Chief Executive Officer of Healthrageous, a behavioral change company launched in 2009 by Partners HealthCare, sold to Humana in September 2013. Most recently, Rick led an investor syndicate in the acquisition of MeYou Health from Healthways in June 2016. He served as the company’s Chief Executive Officer in Boston, MA, until 2017.

He founded Quality Oncology, a cancer disease management firm, in 1995 and was instrumental in the company’s growth and ultimate sale to Matria Healthcare in 2003. In the late 1980s, he was part of the founding team of Value Health, a specialty managed care company that grew to a $1.5-billion initial public offering in 3.5 years.

He is a graduate of Harvard College and the University of Washington School of Public Health, where he received a Masters in Healthcare Administration. Rick began his career in Washington, DC, where he worked for Congressman David Stockman and then rose to be #2 at the National Business Group on Health. He has often been characterized for thinking outside of the box, and coloring outside the lines. He currently sits on the board at CancerLife, M3 Information, and Archetype Solutions Group, and advises and mentors entrepreneurs.

Jeffrey Lombardo, PharmD, BCOP

Associate Director, Empire State Patient Safety Assurance Network, University at Buffalo

Research Assistant Professor, University at Buffalo

Jeffrey Lombardo is Associate Director for the University at Buffalo’s patient safety organization, Empire State Patient Safety Assurance Network, where he facilitates organization participation, logistics, and implementation with participating sites as well as reviewing data and presenting reports on findings. Working with medical oncologists, he is tracking patient outcomes and advising physicians on best practices for patients with cancer, making full use of his specialty pharmacy certification in oncology.

He is also a member of the State University of New York Global Health Institute, where he is bringing his patient safety and oncology expertise to partner schools, such as the University of the West Indies, for various collaborations. In Jamaica, he will be partnering with the University of the West Indies on studies on medical marijuana and pursuing new initiatives for the University at Buffalo’s medication management research network. In addition, he is a member of the University at Buffalo‘s Center for Integrated Global Biomedical Sciences.

He received his Doctorate in Pharmacy from the University at Buffalo, where he currently is a Research Assistant Professor. He has completed research and co-authored several articles on topics involving chemotherapy in the field of solid tumors. He has worked in various cancer pharmacies throughout Western New York, as well as national oncology specialty pharmacies. These roles provided him with expertise in contracting with managed care plans and companies in the pharmaceutical industry.

In addition to these accomplishments, he has exhibited and presented his work both internationally and domestically at the University of the West Indies Research Days, American Society of Clinical Oncology, American Society of Health-System Pharmacists, and Value-Based Cancer Care symposia.

Douglas Long

Vice President, Industry Relations, IQVIA

Douglas Long is Vice President, Industry Relations, IQVIA, the world’s largest pharmaceutical information company and has been with them since 1989. IQVIA offers services to the pharmaceutical industry in more than 101 countries around the world. His fundamental task is to help secure data for all existing and new databases supported by IQVIA; manage supplier, manufacturer, and association relationships; and develop information for data partners. As direct consequence of his involvement in these areas, he has considerable experience with, and a unique perspective on, the changing US and global healthcare marketplace and pharmaceutical distribution.

He is a frequent Industry speaker for the Health Distribution Management Association, National Association of Chain Drug Stores, Food Marketing Institute, National Council of Prescription Drug Programs, Pharmaceutical Care Management Association, National Community Pharmacists Association, International Federation of Pharmaceutical Wholesalers, Generic Pharmaceutical Association, Biotechnology Innovation Organization, Academy of Managed Care Pharmacy, Pharmaceutical Research and Manufacturers of America, Healthcare Supply Chain Association, and more. He was recently the opening speaker at the US Department of Health & Human Services’ Pharmaceutical Forum on Innovation, Access, Affordability, and Better Health. His topic was the balance between innovation and smarter spending.

Douglas is the recipient of the 2016 International Federation of Pharmaceutical Wholesalers’ Leadership Award. This award is given to an industry leader who has demonstrated a commitment to international collaboration and information sharing to assist the International Federation of Pharmaceutical Wholesalers on its mission to help members and stakeholders advance the safe, efficient, and continuous access to pharmaceuticals worldwide through the promotion of good distribution practices and services.

He also received the distinguished Harold W. Pratt Award in 2011, which recognizes individuals whose activities have contributed to the promotion, recognition, and improvement of the practice of pharmacy within the chain drug industry. Prior to receiving the Pratt Award, he was honored with the Healthcare Distribution Management Association’s Nexus Award for lifetime achievement in 2004, the IMS’ prestigious Summit Award in 2003, and the IMS CEO Team award in 2013.

Before joining IMS Health, he held positions at Nielsen Market Research for 16 years in various sales and marketing capacities. A native of Illinois, Doug received a Bachelor of Arts from DePauw University and holds a Masters in Business Administration in management from Fairleigh Dickinson University, Teaneck, NJ.

Steve Lundquist

___Credials___

___Bio___

Sumner Madden

Senior Director, Access Services and US Market Access, AstraZeneca

Sumner Madden is Senior Director, Access Services and US Market Access, at AstraZeneca, where he leads the AstraZeneca Access 360 team that provides reimbursement services for AstraZeneca across the oncology, infectious disease, and respiratory biologics therapeutic areas. He works across the AstraZeneca enterprise to implement integrated patient and provider reimbursement service models designed to streamline access to AstraZeneca specialty medicines. He sets the overall strategy for the patient and provider access services, assesses emerging technologies, service models, and reimbursement trends. The AstraZeneca Access 360 team is responsible for all aspects of specialty reimbursement services, including the Centers for Medicare & Medicaid Services coding submissions, marketing and communications, field reimbursement manager support, and the fully insourced reimbursement HUB services.

Prior to AstraZeneca, he served in various operations and client management roles at Covance Market Access Services, and prior to joining AstraZeneca, he focused on new service and business development. He has more than 15 years of specialty pharmaceutical industry experience across multiple therapeutic areas and disease states with a strong focus on patient and provider access and reimbursement program strategy, implementation, and operations. He has expertise in maximizing the effectiveness of manufacturer HUB programs, including patient affordability programs, technology solutions, and field team integration. He holds a Bachelor of Science degree in biology from Hampton University.

Ash Malik, MBA

President, Advanced Analytics Division, PrecisionQ Intregra Connect

Ash Malik is President, Advanced Analytics Division, PrecisionQ Integra Connect, where he is responsible for designing data- and analytics-driven solutions to enhance precision care products and services offered to patients, physicians, and payers by pharmaceutical and genomic-based life science companies. Prior to PrecisionQ Integra Connect, Ash was Partner, Healthcare Industry Advisory, at the Strategy& group in PricewaterhouseCoopers, where he served clients primarily in oncology and precision medicine on opportunities related to growth, product commercialization, and enterprise-wide strategy design. In addition, he served as Portfolio Director, Global Scientific Strategy, and Marketing Director, Commercial Operations, at Merck, where he participated in developing its US and global scientific strategy for metabolic diseases as well as international commercial operation requirements for biosimilars. Prior to Merck, he was with French multinational bioMeriéux, heading its divisional strategy to introduce molecular and genomics products in US and European markets.

Ash holds a Masters in biochemical engineering from Duke University and a Masters in business administration from the Kenan-Flagler Institute at University of North Carolina, Chapel Hill.

Randy Maloziec

Vice President, BioPharma Relations, US Bioservices

Randy Maloziec is Vice President of BioPharma Relations for US Bioservices, where he heads a team of account managers who are responsible for cultivating relationships with pharmaceutical manufacturers, negotiating agreements and identifying and coordinating cross-functional opportunities to enhance partnerships and increase product access. Also under his leadership is a clinical analytics team that is responsible for developing data services that help our manufacturer partners understand each patient’s journey.

Joining US Bioservices in 2016, he brought nearly 20 years of experience in pharmaceutical commercialization. His experience includes a role as part of AmerisourceBergen’s Global Sourcing and Manufacturer Relations, and 15 years with Eli Lilly and Company, where he worked in multiple roles in contracting sales, training, and operations.

He earned Bachelor of Science degrees in microbiology and biochemistry from the University of Michigan.

Maurie Markman, MD

President, Medicine and Science, Cancer Treatment Centers of America

Maurie Markman is President, Medicine and Science, Cancer Treatment Centers of America. For more than 30 years, he has been engaged in clinical research in the area of gynecologic malignancies, with particular focus on new drug development and exploring novel management strategies in female pelvic cancers. He is a nationally renowned oncologist and was previously Senior Vice President of Clinical Affairs and National Director of Medical Oncology at The University of Texas M.D. Anderson Cancer Center.

Prior to his tenure at M.D. Anderson Cancer Center, he was Chairman of the Department of Hematology/Oncology and Director of the Taussig Cancer Center at the Cleveland Clinic Foundation. He also spent 5 years as Vice Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York City.

He has been the primary author and co-author on more than 1000 published peer-reviewed manuscripts, reviews, book chapters, editorials, or abstracts, and has written/edited/co-edited 23 books on the management of malignant disease. In 2011, he received the American Society of Clinical Oncology’s Statesman Award, which recognizes individual members who have shown extraordinary volunteer service, dedication, and commitment to the society, their hospital community, and the patients they serve.

He received his bachelor degree in biology and graduated summa cum laude. He also holds a masters in health policy and management from New York University Graduate School of Public Administration, and his medical degree from New York University School of Medicine.

William McGivney, PhD

Managing Principal, McGivney Global Advisors

Bill McGivney is the Principal at McGivney Global Advisors, a consulting company established in 2012 to advise pharmaceutical, biotechnology, and medical device companies regarding optimal positioning for drugs, biologics, and medical devices on the market. Dr McGivney has vast experience and expertise that focuses on “real world” issues and strategies.

Prior to his current position, Dr McGivney was the Chief Executive Officer from 1997 to 2011 of the National Comprehensive Cancer Network (NCCN), where he built the NCCN into the most influential organization in the United States. During his tenure at NCCN, Dr McGivney founded the NCCN Drugs and Biologics Compendium. Prior to the NCCN, he was the Vice President, Clinical and Coverage Policy, at Aetna Health Plans from 1991 to 1997.

Dr McGivney has been a member of the Medicare Coverage Advisory Committee, the Liaison to the US Food and Drug Administration for the American Medical Association, and developed and directed the American Medical Association’s Technology Assessment Program, DATTA.

Dr McGivney holds a PhD in Pharmacology.

John McManus

President and Founder, The McManus Group

John McManus is President and Founder of The McManus Group, a consulting firm specializing in strategic policy, political counsel, and advocacy for healthcare clients with issues before the US Congress and the Presidential Administration. The McManus Group services clients who are leaders in their respective field across the healthcare spectrum, from the pharmaceutical, biotechnology, and medical device industries, to physician groups and employee benefit managers. The McManus Group was founded in 2004 and has built a reputation of substantive policy expertise that is trusted by key policymakers in both legislative chambers and in the Presidential Administration.

Prior to founding The McManus Group, he served as Staff Director of the Ways and Means Health Subcommittee, where he led the policy development, negotiations, and drafting of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. This Act provided a market-based, comprehensive prescription drug benefit, reformed Medicare, and established Health Savings Accounts. He worked for Chairman Thomas for 6 years, where he also played an instrumental role in the Medicare Commission, Patients’ Bill of Rights, and other Medicare legislation.

Before working for Chairman Thomas on Capitol Hill, he worked for Eli Lilly and Company as Senior Associate from 1994-1997 and for the Maryland House of Delegates from 1993-1994 as a Research Analyst, briefing the Chairman of the Economic Matters Committee and members of the Health Subcommittee.

He earned his Master of Public Policy from Duke University and Bachelor of Arts from Washington and Lee University. He serves on the Board of Advisors of the Williams School of Commerce, Economics, and Politics of Washington and Lee University.

Geoff Meacham, PhD

Managing Director and Senior Research Analyst, Biotechnology and Pharmaceutical, Barclays Investment Bank

Geoff Meacham joined Barclays in December 2014 and is currently Managing Director and Senior Research Analyst covering the biotechnology and pharmaceutical sectors. He joined Barclays from JP Morgan, where he spent 10 years as Managing Director and Global Head of Biotechnology Equity Research. He has been ranked #2 by Institutional Investor since 2008. He was previously a Biotechnology Analyst at UBS, and prior to his career on Wall Street, he worked in industry at Solvay Pharmaceuticals. He earned a Bachelor of Science degree in biology and microbiology from the University of Georgia, and his Doctor of Philosophy degree in molecular and cellular biology from the University of Alabama at Birmingham.

Annastasiah Mudiwa Mhaka, PhD

Co-Founder, Alliance for Artificial Intelligence in Healthcare

Senior Advisor, Adjuvant Partners

Annastasiah Mudiwa Mhaka is an experienced life sciences executive, investment professional, and biotech entrepreneur with a passion for global health. Leveraging expertise in biomedical discovery, technology development, care delivery, and fundraising, she creates transformative healthcare advances impactful on a global scale. Utilizing her experience in multidisciplinary approaches, she co-founded the Alliance for Artificial Intelligence in Healthcare, a global organization dedicated to resolving the myriad challenges facing the growing field of artificial intelligence and machine learning-based healthcare solutions. She is also Senior Advisor for Adjuvant Partners, where she supports business development and transactions for advanced technologies to industry and academia with a focus on regenerative medicine, computational drug discovery, machine learning, and artificial intelligence.

In addition to her proven track record of more than 50 deals in the private and public sectors, she has generated more than $200 million in deliverables within the drug development and nanotechnology sectors.

She received her PhD in cellular and molecular medicine from Johns Hopkins Medicine, where she developed a clinical phase oncology drug, and attained her Bachelor of Science in chemistry (Highest Honors, Summa Cum Laude) from the University of Pittsburgh.

Tom Michaels

Senior Vice President, Sales, Vivaleas

Tom Michaels is an accomplished executive with strong sales, account management, market access, and new product launch experience. He is currently Senior Vice President, Sales, at Vivaleas, a patient-centered pharmaceutical services organization. He held numerous leadership roles in his 27 years at Novartis before moving to Diplomat Specialty Pharmacy in 2012 as Senior Vice President, Sales and Account Management.

In addition to sales leadership, Tom has in-depth experience in account management, integrated delivery networks, and specialty pharmacy that is vital in the complex world of healthcare today. He is a strong business leader with a proven track record of leading teams, setting strategic plans, and exceeding sales goals. He has led specialty product launches in the pharma and specialty pharmacy settings. Tom has built extensive relationships across payer, pharma, and provider groups. He has a focus on understanding customer needs and bringing value-based solutions to them. Tom has a passion for improving patient care and has helped provide added resources for education, copay funding, and adherence programs.

Tom graduated from Central Michigan University with a Bachelor’s degree in marketing, economics, and information systems analysis. He is also an alumnus of the University of Michigan’s Executive Education program.

Robert S. Miller, MD, FACP, FASCO

Vice President and Medical Director, CancerLinQ

Robert S. Miller is Vice President and Medical Director, CancerLinQ, a big data, health technology platform for oncology developed by the American Society of Clinical Oncology (ASCO). He provides medical oversight and clinical input for all aspects of CancerLinQ’s strategic plan and operations. He serves as primary staff support for the CancerLinQ Physician committees, and he represents ASCO and CancerLinQ in numerous external collaborations to promote cancer data sharing, interoperability, and standards. Previously, he was ASCO Vice President for Quality and Guidelines, responsible for clinical practice guidelines, performance measurement, the Quality Oncology Practice Initiative, and quality informatics.

From 2009 to 2014, he served as Oncology Medical Information Officer at the Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine and specialized in the care of patients with breast cancer. His additional professional experience included the community practice of oncology in California, where he was president of the Sacramento Center for Hematology and Medical Oncology, and Hospice Medical Director.

Dr Miller received his medical degree from the Virginia Commonwealth University School of Medicine where he was the class president and a member of Alpha Omega Alpha. He is board certified in internal medicine, medical oncology, and clinical informatics.

Michael R. Mong, PharmD

Director, Specialty Pharmacy Development, Walgreen Company

Michael R. Mong is Director of Specialty Pharmacy Development at Walgreen Company, where he collaborates with pharmaceutical manufacturers to craft strategies to bring products to market and provides support through implementation and launch.

Prior to moving into an account management role, he held several leadership positions at Walgreens Specialty Pharmacy, including supervising home infusion services, hemophilia, fertility, and limited distribution therapy-focused teams. In 2017, he assisted in creating and leading the first Oncology Therapy Focused Team within Walgreens Specialty Pharmacy—a team dedicated to creating partnerships in the oncology space and offering personalized care to patients. Preceding his time in specialty pharmacy, he spent 5 years as Pharmacy Manager with Rite Aid Pharmacy, assisting with several district initiatives and vaccine administration services.

He received his Doctor of Pharmacy degree from Duquesne University School of Pharmacy in 2010.

Marcus Neubauer, MD

Chief Medical Officer, The US Oncology Network

Marcus Neubauer is Chief Medical Officer for The US Oncology Network (a McKesson company). He has been with McKesson since March 2013. From June 2011 to March 2013, he practiced medical oncology as Associate Professor at the University of Kansas; prior to that he was Medical Oncologist at the Kansas City Cancer Center for 18 years. He has also practiced medicine part-time at the Seattle Cancer Care Alliance for 5 years.

He is a Founding Member and current Chair of The US Oncology Network Pathways Task Force, the committee responsible for developing and updating the industry-leading, evidence-based level 1 pathways. He leads the collaboration with the National Comprehensive Cancer Network (NCCN) to build a premium set of guidelines and pathways that will assist the oncology community in driving value-based, high-quality cancer care. The combined product is called Value Pathways powered by NCCN. His area of interest is the emergence of value-based care models and practice transformation to provide value-based care.

He received his Bachelors of Science degree at the University of Washington in 1984 and his medical degree at the University of Kansas in 1988. He completed his oncology/hematology fellowship at the University of Washington in 1993. He is on the editorial board for the Journal of Oncology Practice, and has served as Co-Chair of the Lung Cancer Committee for US Oncology Research for 6 years.

Dr Neubauer resides in his native hometown, Seattle, Washington with his wife, Michele. He has 2 children.

Brenda Nevidjon, RN, MSN, FAAN

Chief Executive Officer, Oncology Nursing Society

Brenda Marion Nevidjon is Chief Executive Officer of the Oncology Nursing Society, a professional association of more than 39,000 members committed to promoting excellence in oncology nursing and the transformation of cancer care. Her career in United States, Switzerland, and Canada has included clinical, academic, and executive positions in both the cancer care and the broader healthcare delivery environments. She was the first nurse and the first woman appointed as Chief Operating Officer of Duke University Hospital in 1996.

Brenda received her bachelor’s degree from Duke University, her master’s degree from the University of North Carolina, and she has done doctoral work at the Fielding Graduate Institute and Duke School of Nursing. Among other recognitions, she is a Fellow in the American Academy of Nursing and serves on the Advisory Committee of the Biden Cancer Initiative.

Everett Neville, RPh

Executive Vice President, Strategy, Supply Chain & Specialty, Express Scripts Holding Company

Everett Neville joined Express Scripts in 1998 and is Executive Vice President, Strategy, Supply Chain & Specialty. He is responsible for leading all aspects of strategy, supply chain, and the specialty business, using his unique understanding of the pricing and reimbursement landscape to champion the needs of clients in Express Scripts’ relationships with pharmaceutical manufacturers. His leadership abilities and in-depth experience make him an important part of the Express Scripts team, with a unique perspective in the PBM industry. His pioneering approach to pharmaceutical relationships and negotiation has led to novel solutions that lower costs while improving pharmacy care.

In his current role, he oversees the company’s supply chain, specialty, and corporate strategy functions. In supply chain, he focuses on leveraging the scale to drive better value and pricing from Express Scripts’ pharmaceutical companies, retailers, and wholesalers in support of driving better price, value, and outcomes for our payers and patients. In specialty pharmacy, he leads teams to drive a superior patient experience, improving their outcomes while also delivering value for the physicians and payers by ensuring the company gets the right drugs to the right patient at the right time at the right price. In strategy, he drives the strategic vision and specifically focuses on creating better value for the integrated PBM clients, using the core strengths to develop new products and value streams to lead our strategic pursuits.

He has had a varied career, including serving as Senior Director for the Centers of Medicare & Medicaid Services; and Vice President in areas such as clinical program management, account management, health plans, and pharma strategies and contracting. He is a pharmacist by training, and has worked as Staff Pharmacist in the University of North Carolina Hospital system.

He earned a Bachelor of Science in pharmacy from the University of North Carolina in Chapel Hill and received his Master of Business Administration from the University of Missouri–St. Louis.

Ben Newton, PhD

Global Head, Life Sciences Molecular Imaging, GE Healthcare

Ben Newton is Global Head of Life Sciences Molecular Imaging at GE Healthcare in Amersham, Buckinghamshire, United Kingdom. He has more than 20 years’ experience in the life science, diagnostics, and pharmaceutical industry. He leads the development and commercialization of Life Sciences’ digital ecosystem, predictive analytics, services, and solutions, helping academia, pharmacists, and clinicians discover, develop, manufacture, and deliver precision medicine.

He received his Bachelor of Science degree in pharmacology and immunology from the University of Leeds, and his doctorate in medicine from Imperial College London.

Amy Niles, MBA

___Credials___

___Bio___

Kimberly Noonan, PhD

Co-Founder and Chief Scientific Officer, WindMIL Therapeutics

Kimberly Noonan is Chief Scientific Officer and Co-Founder of WindMIL Therapeutics along with Ivan Borrello, MD. Together Drs Borrello and Noonan pioneered the use of marrow infiltrating lymphocytes for the treatment of cancer.

She has published many peer-reviewed papers, review articles, and book chapters and holds several patents. She joined the faculty of Johns Hopkins University in 2004 and maintains an adjunct faculty appointment.

She received her Bachelor of Science degree in microbiology and her PhD in immunology from the University of Pittsburgh. She also holds a Master of Public Health from Johns Hopkins University.

Andrew Norden, MD, MPH, MBA

Chief Medical Officer, Cota Healthcare

Andrew Norden is a Neuro-Oncologist and Physician Executive who joined Cota Healthcare in 2017 as Chief Medical Officer. Prior to joining Cota, he served as Deputy Chief Health Officer and Lead Physician, Oncology and Genomics at IBM Watson Health. Previously, he worked at Dana-Farber Cancer Institute in Boston in several capacities, including Associate Chief Medical Officer and Medical Director of Satellites and Network Affiliates. He served as Physician Leader for the Dana-Farber community network for more than 5 years.

A talented physician and board-certified neurologist and neuro-oncologist, he cares for patients with brain tumors and neurologic complications from cancer. He has also developed many clinical trials for patients with glioma, meningioma, and seizures in patients with brain tumors.

He is the author of more than 65 peer-reviewed papers primarily involving therapy for high-grade gliomas and meningioma. He is an active member of the American Society of Clinical Oncology, the Society for Neuro-Oncology, and the American Academy of Neurology, and he is Associate Editor of JCO-Clinical Cancer Informatics.

He attended Yale School of Medicine before moving to Boston for residency training at Massachusetts General and Brigham and Women’s Hospitals. After serving as Chief Resident, he completed a neuro-oncology fellowship at Dana-Farber. He also earned a Master of Public Health degree from Harvard School of Public Health and a Master of Business Administration from the University of Massachusetts, Amherst. His received his undergraduate degree in neuroscience from Brown University.

He lives outside Boston with his wife and 3 young sons. In his free time, he enjoys snow-skiing, running, and watching his sons play sports.

Gary Owens, MD

___Credials___

___Bio___

Gitesh Patel

Chief Executive Officer, Sargas Pharmaceutical Adherence & Compliance International

Director, Business Development, Comprehensive Blood and Cancer Centers

Gitesh Patel is Chief Executive Officer at Sargas Pharmaceutical Adherence & Compliance International, and Director of Business Development at the Comprehensive Blood and Cancer Centers, Bakersfield, CA. He is a healthcare executive with decades of experience in building relationships with physicians, health professionals, pharmaceutical companies, insurance companies, and medical equipment companies.

He has developed various revenue streams, such as office dispensing; the Chronic Care Management Physician, Patient and Pharmacy Portals® with the Mobile Medication Treatment Monitoring for Medication Adherence® to reduce healthcare costs; Transition Care Management® to reduce hospital readmissions; and ancillary health service lines for specialty health clinics and cancer centers.

He has been a consultant for reimbursement issues, regulatory environment, financing, mergers, acquisitions, partnerships, and collaborations in the healthcare and pharmaceutical industries.

He received his Bachelor of Science degree in physics from Gujarat University in Ahmedabad, India, and has attended Cornell University and the University of Phoenix to further his education. He enjoys playing golf with his son and getting involved in community fundraising events for cancer, religious charities, and other community needs.

Kavita Patel, MD, MS, FACP

___Credials___

___Bio___

Pamela M. Pelizzari, MPH

Principal and Senior Healthcare Consultant, Milliman

Pamela M. Pelizzari is a Principal and Senior Healthcare Consultant at Milliman in New York, NY. She specializes in the development and management of episode-based payment methodologies. She joined the firm in 2014. Prior to joining Milliman, Pamela served as a Senior Technical Advisor at the Centers for Medicare & Medicaid Services, where she was responsible for developing and implementing novel payment methodologies to transform healthcare delivery and payment nationwide. She played a key role in designing the National Bundled Payments for Care Improvement initiative, with thousands of participants nationally. She also led the development of an oncology episode-based payment model as well as other specialty physician–focused bundled payment models.

She has a broad background in integrated delivery system administration and healthcare payment reform. She has worked in the clinical and payer settings, and has experience in alternative risk contracting strategies. Previously, Pamela has worked at an academic medical center, building consensus for redesigning care delivery among diverse stakeholders, including physicians, administrators, and patient advocates.

She has particular expertise in the analysis of healthcare claims and the development of episode-based payment definitions and benchmarking methodologies. Pamela also has experience implementing prospective and retrospective payment methodologies, including developing gain-sharing methodologies, claims adjudication techniques, and quality monitoring programs.

In recent years, Pamela has published papers in academic journals, such as Lancet and Circulation. She has also spoken at numerous national conferences on the topic of episode-based payment models and methodologies.

Pamela received her Bachelor of Arts degree in community health and her Bachelor of Science degree in applied mathematics from Brown University, Providence, RI. She obtained her Master of Public Health degree in healthcare policy and administration from Johns Hopkins University Bloomberg School of Public Health.

Steven R. Peskin, MD, MBA, FACP

Executive Medical Director, Population Health, Horizon Blue Cross Blue Shield of New Jersey

Steven R. Peskin is Executive Medical Director, Population Health, at Horizon Blue Cross Blue Shield of New Jersey. His expertise encompasses physician leadership, medical delivery management, performance improvement in healthcare, contracting, applications in technology including mobile and social media, and clinical and scientific communications for healthcare professional and consumer audiences.

He is former Executive Vice President and Chief Medical Officer for MediMedia USA; Chief Executive Officer of Pharmaceutical Research Plus; President and Chief Operating Officer of Nelson Managed Solutions; and has worked in multiple executive positions in health plans at PacifiCare Health Systems, CIGNA Healthcare, and John Hancock. He has authored industry and scientific articles, book chapters, and has spoken at various conferences and events about physician leadership, the medical home, mobile health, and social media.

He is Associate Clinical Professor in the Department of Medicine at Rutgers Robert Wood Johnson Medical School. He is a clinical preceptor at The Eric B. Chandler Clinic for interns and residents in internal medicine. He also assists with the Population Health and Business of Medicine training for the Rutgers Robert Wood Johnson Internal Medicine physicians in training.

He is a Diplomat of the American Board of Internal Medicine and a Fellow of the American College of Physicians; serves as Governor for the Southern Region of the American College of Physicians in New Jersey; Board of Trustees for Friends of the National Library of Medicine; and serves on the Editorial Advisory Boards of The Journal of Population Health Management and Managed Care; and is a Senior Scholar in the School of Population Health at Thomas Jefferson University. His community service includes the Boards of the Greater Donnelley Neighborhood Initiative and Young Audiences of New Jersey.

He received his bachelor’s degree from The University of North Carolina Chapel Hill and a medical degree from Emory University School of Medicine. He completed residency at Saint Elizabeth’s Medical Center in Boston and holds a Master in Business Administration from the Sloan School of Management at Massachusetts Institute of Technology.

Chad Pettit

Executive Director, Global Value Access and Policy, Biosimilars Business Unit, Amgen

Chad Pettit is Executive Director, Global Value Access and Policy, Biosimilars Business Unit, Amgen, where he develops global market access launch strategies for Amgen’s portfolio of 10 biosimilar medicines and leads across the biopharmaceutical industry on biosimilar policy matters, in a new and rapidly growing segment of the industry and growth business for Amgen. With his global perspective, he is recognized as an expert on biosimilar commercialization and market access for biosimilars and the policy measures required to facilitate cost-savings to patients and the healthcare system over the long run for these promising medicines.

His nearly 20 years of experience at Amgen have included service as the Amgen Board Member of the US Biosimilars Forum Industry Trade Group and a career focus on pricing, market access, and policy, crossing all global regions in a broad range of roles in the United States and Europe.

He received his Master in Business Administration from the University of California Los Angeles, Anderson School of Management, and holds a Bachelor of Science degree in chemical engineering from the University of California Davis.

Kip Piper, MA, FACHE

President, Health Results Group

Kip Piper is President of the Health Results Group, a strategic advisory firm, and Chief Executive Officer and Founder of Medonomics, a nonprofit health policy research organization dedicated to market-based solutions to improve value and decision-making. He is also Senior Advisor to ADVI Health and Executive Advisor to COPE Health Solutions.

He is an authority on Medicare and Medicaid and is a prominent consultant, speaker, and author. A skilled business and policy strategist, he solves problems and creates opportunities for life sciences companies, health plans, hospitals and health systems, major provider organizations, state Medicaid agencies, and private equity firms. He has also advised governors, members of Congress, Fortune 100 employers, foundations, and foreign leaders.

Across Medicare, Medicaid, and health reform, he advises clients on policy, finance, and business strategy. This includes coverage, reimbursement, payment and delivery reform, patient access, managed care, business development, product launches, strategic communications, waivers, market and policy intelligence, and federal and state legislation, regulations, budgets, and procurements.

He has more than 30 years of experience, including senior advisor to the administrator of the Centers for Medicare & Medicaid Services; Wisconsin State Health Administrator and State Public Health Officer; director of the multibillion-dollar Wisconsin Medicaid program; Senior Medicare Budget Officer at the White House Office of Management and Budget; Advisor to Fortune 500 employers; Presidential Management Fellow; and director of national, foundation-sponsored initiatives on payment reform, value‐based purchasing, and state‐based health reform. He has also served in local elective office as County Board Member and Chief Executive of a small municipality.

Often called upon to help solve complex and intractable issues, he has testified before the US House and Senate committees and state legislatures, and has drafted and negotiated major legislation. He is widely quoted in the press, including the Wall Street Journal, USA Today, BusinessWeek, Politico, Inside CMS, Fox Business News, CBS News, National Journal, National Public Radio, Modern Healthcare, The Hill, HealthLeaders, Medpage Today, Investor’s Business Daily, Managed Healthcare Executive, and Associated Press.

A popular speaker at healthcare conferences and author of numerous journal articles, he speaks and writes often on Medicare, Medicaid, and health reform. He blogs at PiperReport.com and serves on the editorial board of American Health & Drug Benefits, a peer‐reviewed journal.

Board certified in healthcare management, he is a Fellow of the American College of Healthcare Executives and holds a Masters in public policy and administration from the University of Wisconsin, Madison.

Scooter Plowman, MD, MBA, MHSA

Medical Director, Digital Medicines, Proteus Digital Health

Scooter Plowman is Medical Director, Digital Medicines, at Proteus Digital Health, a leading innovator spearheading the development of digital medicines. He leads the Clinical Implementation Teams, Clinical Strategy, and Business Development for the Digital Medicines department through partnerships with health systems across the United States. He also communicates the evidence of Digital Medicines in target treatment areas to external audiences. Prior to joining Proteus, he was a fellow at the Stanford University Clinical Excellence Research Center, and a practicing physician for SimonMed Imaging.

He completed his fellowship at Stanford in Health System Design and Value-Based Care. He holds a medical degree, a Master in Business Administration, and a Master in Healthcare Administration from the University of Kansas, and completed his postgraduate medical training at the Mayo Clinic and Intermountain Healthcare. He also has a Master of Science in diagnostic imaging from the University of Oxford.

Jill Pollander, RN, MSN

Director, Patient Services, National Organization for Rare Disorders

Jill Pollander is Director of Patient Services at the National Organization for Rare Disorders. As a registered nurse, she has more than 25 years of diverse professional healthcare experience from the emergency department to long-term care with a specialty in pain management and palliative care. As the founding chair of a nursing program at a small proprietary college, she was able to share her diverse experience with future healthcare practitioners. As a nurse, she is a fierce advocate for patients and their access to care and treatment.

Prior to joining the National Organization for Rare Disorders, she was Assistant Vice President of Underwriting and Physician Services for a large New York State professional liability insurer, Hospitals Insurance Company. Her unique background has enabled her to see healthcare and healthcare economics from many perspectives.

She received her Bachelor of Science in nursing from Northeastern University and her Master of Science in nursing from the University of Phoenix.

Bruce Pyenson, FSA, MAAA

Principal and Consulting Actuary, Milliman

Bruce S. Pyenson is Principal and Consulting Actuary with Milliman in New York, NY. He joined the firm in 1987. Bruce’s practice uses data science and actuarial science to address pressing issues in healthcare. In his career, he has consulted to almost every sector of the healthcare industry, including accountable care organizations, employers, advocacy groups, insurers, and the biotechnology industry. Many of his projects involve integrating analytics from financial, clinical, and operational models.

In recent years, client projects have included the cost-benefit of lung cancer screening, the cost advantage of computed tomography colonography, the effect of changes in exchange benefit design, marginal cost analyses using risk adjustment methodologies, feasibility analyses for accountable care organizations, restructuring of disease management processes, and actuarial cost/benefit evaluations for pharmaceutical manufacturers.

In 2016, Bruce was appointed to a 3-year term as Commissioner of the Medicare Payment Advisory Commission, serving in a position reserved for an actuary. He was on the board of the Health Project (Koop Awards) from 2010 to 2016.

Bruce has co-authored approximately 30 peer-reviewed publications on topics ranging from lung cancer screening to survival in hospice, medication errors, and reinsurance for expensive biotechnology products. He was the editor and co-author of Managing Risk: A Leader’s Guide to Creating Successful Managed Care Provider Organization (AHA Publishing, 1998) and Calculated Risk: A Provider’s Guide to Assessing and Controlling the Financial Risk of Managed Care (American Hospital Publishing, 1995). He has also authored several Milliman research reports on topics such as obesity, hepatitis C, hospital outpatient trends, healthcare reform, and programs for the disabled elderly. He is a frequent speaker on issues related to system change.

He is a Fellow of the Society of Actuaries and a member of the American Academy of Actuaries.

Michael Reff, RPh, MBA

Founder and Executive Director, National Community Oncology Dispensing Association

Manager, The Patient Rx Center, Hematology/Oncology Associates of Central New York

Michael Reff is Founder and Executive Director of the National Community Oncology Dispensing Association, the first patient-focused organization dedicated to proactively help shape the oncology value proposition with regard to in-office dispensing. In addition, he continues practicing at Hematology/Oncology Associates of Central New York, where he established The Patient Rx Center, a medically integrated dispensing service focused on positive patient experiences with specialty medications.

He serves on the American Society of Clinical Oncology’s Quality Oncology Practice Initiative Steering Group Task Force. He also served on the Association of Community Cancer Centers’ Editorial Board, Government Affairs Committee, National Renal-Cell Carcinoma Advisory Committee, and Dispensing Pharmacy Project Committee. He shares his passion for patients with regard to the importance of the continuity of care for oral oncolytics through delivering presentations and publishing articles. He has extensive pharmaceutical industry experience spanning many disciplines, including oncology research, oncology sales, corporate compliance, international supply chain, and biologics manufacturing.

He received his Bachelor degree in pharmaceutical sciences and administration from Albany College of Pharmacy of Union University, and obtained his Master of Business Administration in finance from Le Moyne College.

Scott Reid, PharmD

President, Medical Oncology, Lab Management, Radiation Therapy, and Specialty Drug, eviCore Healthcare

Scott Reid joined eviCore Healthcare in 2013, and is currently President of Medical Oncology, Lab Management, Radiation Therapy, and Specialty Drug. He has 35 years of business, clinical, and operations experience in various healthcare and pharmacy settings, including hospital, retail, home infusion, and specialty pharmacy.

Prior to his role at eviCore Healthcare, he was Senior Vice President of Specialty Pharmacy for CVS Caremark, where he was responsible for specialty pharmacy operations, new program and service development, performance improvement, and professional practice. While at CVS Caremark, he led the development of programs for utilization and medication therapy management of specialty drugs used to treat more than 25 chronic and rare diseases as well as programs in oncology.

He is a recognized leader in the home care and specialty pharmacy fields, and has been a member of the URAC Pharmacy Advisory Committee and the Joint Commission on Accreditation of Healthcare Organizations’ Standards Development Committee.

He received his Bachelor of Science degree in pharmacy from Rutgers, The State University of New Jersey College of Pharmacy and his Doctor of Pharmacy degree from Mercer University Southern School of Pharmacy. He also completed a postgraduate residency in home nutrition support and infectious disease.

Robert Rifkin, MD, FACP

Medical Director, Biosimilars, McKesson Specialty Health/US Oncology Network

Robert Rifkin is Medical Director for Biosimilars at McKesson Specialty Health/US Oncology Network, where he oversees clinical research in biosimilars and participates in strategic development for their introduction into the US marketplace.

Prior to his current position, he has served as Clinical Assistant Professor, Department of Internal Medicine, Section of Hematology and Oncology, at the University of Arizona, where he co-founded the University of Arizona Stem Cell Transplant Program. He currently has a private oncology and hematology practice at the Rocky Mountain Cancer Centers, where he continues to be involved in hematopoietic stem-cell transplantation and serves as Consultant for the Foundation of Accreditation of Cellular Therapy. He also holds an appointment as Clinical Associate Professor of Internal Medicine-Division of Medical Oncology at the University of Colorado Health Sciences Center.

He is a member of the Executive Board of Directors for the National Patient Advocate Foundation and the Patient Advocate Foundation, where he first became involved with biosimilars as a patient advocate and educator. He has received the National Marrow Donor Program Trailblazer Award and has been listed multiple times in America’s Top Physicians.

He is the author and co-author of more than 35 peer-reviewed articles, 8 book chapters, and over 75 abstracts. He has special interest in multiple myeloma, novel drug development, and in the development and introduction of biosimilars into the US market.

He received his Bachelor of Arts degree from The Colorado College and his medical degree with honors from the University of Colorado Health Sciences Center School of Medicine.

Darin T. Rubin, MPH, MBA

Founding Partner and Managing Director, Dedham Group

Co-Founder and Partner, Pulse Digital

Darin T. Rubin has spent the past 20 years as a healthcare strategist focusing on the oncology and specialty therapeutics landscape and drawing upon a knowledge base of biomedical sciences, epidemiology, managed markets, distribution models, and commercialization strategy. As Founding Partner and Managing Director of the Dedham Group, a leading oncology and specialty strategy consultancy, his work centers on advising management of pharmaceutical and biotechnology clients across a multitude of specialty therapeutic areas, technology platforms, and regional access ecosystems.

At the forefront of local level access strategies that engage emerging access influences (eg, pathways, alternative payment models, quality and value dynamics, digital therapeutics, molecular diagnostics, technology-based partnerships), Darin has helped his clients anticipate, target, and execute to address rapidly evolving customer and competitive needs. He is also Partner and Co-Founder of Pulse Digital, a specialty therapeutics quality and value data provider.

He completed a Master in Public Health in healthcare policy and management from Columbia University, a Master of Business Administration in healthcare management from the University of Connecticut, postgraduate studies in molecular biology at Columbia University, and a Bachelor of Science in biochemistry from the University of Vermont.

Morrie Ruffin

___Credials___

___Bio___

Michael Ruiz de Somocurcio, MBA

Vice President, Payer and Provider Collaboration, Regional Cancer Care Associates

Michael Ruiz de Somocurcio is Vice President, Payer and Provider Collaboration, for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and the Centers for Medicare & Medicaid Services, and supporting growth strategies in new and existing markets. Prior to joining Regional Cancer Care Associates, he spent more than 15 years on the health plan side working for national, regional, and start-up health plans. Most recently, he held Chief Operating Officer and Vice President positions at Amerigroup, Oscar Insurance, and AmeriHealth NJ, where he led network contracting, strategic initiatives, and medical cost containment.

Throughout his career, he has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals, and physician groups, and he speaks nationally on these topics.

He received his Bachelor of Science degree in business administration from The College of New Jersey and a Master in Business Administration from Rutgers, The State University of New Jersey.

Greg Russotti, PhD

Vice President, Cell Therapy Technical Development, Celgene

Gregory Russotti is currently Vice President of Cell Therapy Technical Development at Celgene, where he is responsible for the process development, analytical method development, product sciences, and process/assay support for, and technology transfer into, clinical and commercial manufacturing for cell therapy products.

Prior to joining Celgene in 2006, he spent 15 years at Merck Research Laboratories developing products that included live virus vaccines, monoclonal antibodies, recombinant vaccines, and microbially produced natural products. He worked on development, scale-up, and technology transfer of cell culture, microbial fermentation, and downstream isolation processes to clinical and commercial manufacturing facilities.

He received his Bachelor of Science and his Master of Science in chemical engineering from Rensselaer Polytechnic Institute, and his PhD in chemical and biochemical engineering from Rutgers, The State University of New Jersey.

Edward C. Saltzman

Executive Chairman and Founder, Defined Health

Edward C. Saltzman is Executive Chairman and Founder of Defined Health. He possesses a vast knowledge of the pharmaceutical and biotechnology industry that he accumulated over Defined Health’s 25+ years of consultancy to pharmaceuticals, biotechnology, specialty pharmacies, and investors. From this breadth and depth of experience, he provides guidance to Defined Health’s senior project leadership who work with clients across multiple therapeutic areas.

Prior to founding Defined Health, he held positions at the Ayerst Laboratories unit of American Home Products, where he had responsibility for evaluation and forecasting of compounds being considered for licensing, and at FIND/SVP where he managed the Healthcare Information Center.

He is a well-regarded and in-demand speaker on industry issues and has been recognized widely as an early “spotter” of key trends that continue to have significant impact within the life sciences industry, especially as these pertain to the licensing and business development field. He has spoken over the past 15 years to large audiences at Defined Health’s Therapeutic Insight and Cancer Progress conferences, the Licensing Executives Society Annual Meeting, and numerous industry conferences. In addition to these public events, he has presented targeted strategy briefings and held discussions privately with scores of boards of directors, executive management committees, and licensing and business development teams at large pharmaceutical, specialty pharmacy, and biotechnology companies.

He is a member of the Licensing Executives Society and the New York Pharma Forum, and is a graduate of New York University. He serves on the Board of Directors for Vidac Pharma.

Marc Samuels

Founder and Chief Executive Officer, ADVI Health

Marc Samuels is Founder and Chief Executive Officer at ADVI Health. He founded its predecessor, HillCo HEALTH in 2008, and oversees all of the firm’s global activities. ADVI is one of the most active consulting firms in the life science and healthcare services sectors, with a focus on policy, strategy, and commercial development, and has offices in Austin, TX, Chicago, IL, and Washington, DC. Clients include Chicago Pacific Founders and Kleiner Perkins, and Warburg Pincus; the top 15 biotechnology companies; top 10 diagnostic companies; and most of the top device companies all in global sales. He advises clients on business strategy, forecasting, and due diligence; reimbursement and market access issues; and on beneficial policy strategies, including those developing new delivery of care models, innovative pilot programs, and advocacy critical to successful policy, regulatory, and legislative outcomes.

Prior to ADVI and HillCo HEALTH, he was a partner at HillCo Partners, consistently ranked as the top advocacy firm in Texas. Marc served both President George H.W. Bush and President George W. Bush in the White House Office of Policy Development, the Council on Competitiveness, and in the Governor’s Policy Office and the Texas Health and Human Services Commission, respectively. His areas of responsibility included the Medicare Part B and Part D programs, which includes physician, medical device, diagnostic, and biopharmaceutical issues; as well as the Texas state Medicaid program, including managed Medicaid and the Texas Vendor Drug Program.

He began his consulting career with his first partner, J. Michael Hudson, a former Health Care Finance Administration’s Deputy Administrator under President Bush and former Office of Management and Budget official under President Reagan.

He has been named one of the most popular lobbyists for Medicare by the Boston Globe. His comments and analyses have appeared in STAT News, The Pink Sheet, Fierce, In Vivo, Journal of Oncology Practice, Medical Economics, the Fort Worth Star-Telegram, Dallas Morning News, and Texas Medicine. He is a contributor to the third edition of the Managed Care Answer Book and the second edition of the HMO and Capitation Answer Book, published by Panel Publishers, New York. He is policy counsel to the National Comprehensive Cancer Network and on their Foundation Board of Advisors.

He attended Yale School of Medicine’s MPH program, the University of Texas School of Law, and the University of Michigan, where he focused on neuroscience.

Charles Saunders, MD

Chief Executive Officer, Integra Connect

Charles Saunders is Chief Executive Officer at Integra Connect. He is a physician executive who combines a clinical, business, and technology background. He was formerly Chief Executive Officer of Healthagen (an Aetna company), which provides population health technology and services. He has also held previous leadership roles, including Chief Executive Officer of Broadlane, a large group purchasing organization and supply chain technology company; President of EDS Healthcare Global Industry Group; and Chief Medical Officer of Healtheon/WebMD.

As an emergency medicine physician, he headed the EMS Services in the City of San Francisco. He received his medical degree from Johns Hopkins University and a Bachelor of Science in biology from the University of Southern California.

Dennis Scanlon, PhD

Distinguished Professor, Health Policy and Administration

Director, Center for Health Care and Policy Research, College of Health and Human Development, Pennsylvania State University

Dennis Scanlon is Distinguished Professor, Health Policy and Administration; Director, Center for Health Care and Policy Research, College of Health and Human Development; and the NCAA Faculty Athletics Representative, Pennsylvania State University.

His research focuses on understanding the role of measurement, incentives, quality improvement, and individual and organizational behavior change for improving important healthcare outcomes, including clinical quality, patient experience, and economic efficiency. He serves on the editorial board of journals, such as Medical Care Research and Review, the American Journal of Managed Care, and Health Services Research. He is currently serving as Associate Editor at the American Journal of Managed Care and Senior Associate Editor at Health Services Research.

He has served on several national, local, and international advisory panels for organizations such as the Agency for Healthcare Research and Quality, the National Quality Forum, the Commonwealth of Pennsylvania, and the European Commission. Currently, he is a co-investigator of the Agency for Healthcare Research and Quality’s Center of Excellence award focused on understanding healthcare delivery systems and the degree to which they adapt patient-centered outcomes research evidence. He also served as Principal Investigator for the evaluation of the Aligning Forces for Quality initiative, Robert Wood Johnson Foundation’s signature effort to improve the health and healthcare of 37 million people nationwide. He has published more than 100 articles, book chapters, and reports, and is a frequent speaker to academic, policy, and practice audiences.

In January 2017, he was named Distinguished Professor of Health Policy and Administration at Pennsylvania State University, in recognition of his outstanding contributions to the College of Health and Human Development and the University. He was the 2014 recipient of the Evan G. and Helen G. Pattishall Outstanding Research Achievement Award, an award that honors a faculty member’s outstanding research contributions occurring or culminating within the past several years. In 2005, he was the recipient of the Fran and Holly Soistman Faculty Development Award, which honors a faculty member’s engagement in significant, innovative research related to the design, development, delivery, administration, or evaluation of healthcare services. He received the John D. Thompson Prize for Young Investigators in 2002, given annually by the Association of University Programs in Health Administration to an outstanding young investigator in the field of health services research. He also was awarded the Robert Wood Johnson Foundation’s Investigator in Health Policy Research Award in 2002.

In addition to teaching, research, and service on many college- and university-wide committees, he was appointed by the University President in July 2017 to serve as the NCAA Faculty Athletics Representative for Pennsylvania State University in University Park. In this role, he serves as an ex-officio member of the Senate Committee on Intercollegiate Athletics and as the primary liaison between the Athletic Director and the Faculty Senate.

He completed a Bachelor’s degree at Villanova University, earned a Master’s degree in economics from the University of Pittsburgh, and completed his Doctorate in health services organization and policy at the University of Michigan.

Patrick M. Schmidt

Founder and Chief Executive Officer, FFF Enterprises

Patrick M. Schmidt is Founder and Chief Executive Officer of FFF Enterprises since 1988. He is recognized as a leader in the healthcare community, having introduced several industry firsts that have paved the way to create solutions to challenges faced by healthcare providers and their patients. He established FFF with the mission of making the biopharmaceutical supply chain more secure and to achieve the goal of Helping Healthcare Care. Through the Guaranteed Channel Integrity, he has centralized his focus on securing the pharmaceutical supply chain by pledging to purchase product directly from the manufacturer, and ship only to licensed healthcare professionals, which has resulted in more than 30 counterfeit-free years of product distribution, and more than 100 million lives that have been protected.

He has helped to solve the issue of timely recall notifications through the Lot-Track service, which tracks products by lot number and provides customers with an electronic recall announcement within 4 hours of the manufacturer-initiated recall. He has developed 2 online product-ordering systems as well: MyFluVaccine and BioSupply.

In 1995, he also founded NuFACTOR Specialty Pharmacy, a subsidiary of FFF Enterprises that provides immune globulin, coagulation factors, and vaccines directly to patients.

FFF Enterprises has a long tradition of giving back to the communities they serve and support organizations such as Save One Life, the Eric Dostie Memorial College Scholarship, I Give For Kids, the Jeffrey Modell Foundation, the National Hemophilia Foundation, the Neuropathy Action Foundation, The Myositis Association, The Neuropathy Association, The Joey Holt Foundation, and Advocacy for Patients with Chronic Illness.

Theresa Schmidt, MA, PMP, CSPO

Director, Discern

Theresa Schmidt is Director at Discern and has more than a decade of experience in healthcare policy, quality, and health information technology, and leverages a strong background in nonacute care, analytics, quality measures, quality improvement, project management, and agile product development methodologies to help Discern clients and partners achieve their business goals.

Prior to joining Discern, Theresa served as Chief Data and Quality Officer for the National Partnership for Hospice Innovation, where she led the Data and Quality Initiative and worked with hospices and other stakeholders across the United States to better define, measure, and improve quality in hospice. Concurrently, she was Vice President of Strategy at Healthsperien, working with provider and association clients to develop and execute business strategies, led grants and consulting projects, and produced research on a variety of healthcare topics.

She has also worked at Avalere Health, where she directed large-scale projects in the Data Analytics Practice and was Product Manager for Avalere Quality Measures Navigator, overseeing the product’s strategy, roadmap, development, launch, and go-to-market activities.

She previously served the post-acute and long-term care community as Manager of Education at eHealth Data Solutions, where she headed product implementation, support, and documentation. During her 8 years at eHealth Data Solutions, she worked closely with post-acute care/long-term care providers across the United States and collaborated in the software development process, providing subject matter expertise in quality, reimbursement, and performance improvement.

Jeffrey Scott, MD

Chief Medical Officer, Integra Oncology

Jeffrey Scott is Chief Medical Officer at Integra Oncology. He has significant experience building market-leading initiatives in community practice and group purchasing organizations, bringing a multitude of innovative programs and organizations to the marketplace. He has helped lead and build one of the largest community oncology practices, Georgia Cancer; co-founded the International Oncology Network and associated specialty group purchasing organizations; co-founded P4 Healthcare, a multimedia oncology communication and education company; and most recently helped to transition the P4 business to its acquirer, Cardinal Health.

He holds a medical degree from Wayne State University and Bachelor of Science in microbiology and immunology from University of Michigan.

John Simmons, PhD

Director, Translational Science and Diagnostics, Personal Genome Diagnostics

John Simmons is Director of Translational Science and Diagnostics at Personal Genome Diagnostics (PGDx), a cutting-edge next-generation sequencing cancer diagnostic company empowering the fight against cancer by developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. He leads PGDx’s scientific strategy and clinical diagnostics development partnerships with pharmaceuticals and biotechnologies.

He joined PGDx from the National Cancer Institute, where his translational research focused on identifying drug combinations and associated biomarkers.

He received his Doctor of Philosophy degree in tumor biology from Georgetown University.

Greg Simon, JD

President, Biden Cancer Initiative

Greg Simon is President of the Biden Cancer Initiative. He previously served as Executive Director of the White House Cancer Moonshot Task Force, a position created by former President Barack Obama, and for which he was chosen by Vice President Joe Biden in March 2016. Over 9 months, Greg and his team helped launch more than 70 innovative collaborations. Greg returned to the White House after serving as Vice President Al Gore’s Chief Domestic Policy Advisor between 1993 and 1997. He was Chief Executive Officer of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. Previously, Greg was Senior Vice President for Worldwide Policy and Patient Engagement at Pfizer; co-founded with Michael Milken, FasterCures and The Center for Accelerating Medical solutions; and with Leon and Debra Black, he co-founded the Melanoma Research Alliance. He is a cancer survivor, having been recently successfully treated for chronic lymphocytic leukemia.

He received his Bachelor of Arts degree in psychology from the University of Arkansas, and his Juris Doctorate in Law from the University of Washington School of Law.

Surya Singh, MD

Corporate Vice President and Head, Specialty Client Solutions, CVSHealth

Surya Singh is Corporate Vice President and Head of Specialty Client Solutions at CVSHealth, where he is responsible for the company’s specialty client and clinical strategy, product innovation, analytics, and clinical program management. In this role, he leads a multifaceted team of clinicians and analysts, manages the company’s external partnerships in relevant areas, and participates in a variety of strategic initiatives.

Prior to joining CVSHealth, he was Chief Medical Officer and Head of Product Development and Strategy at Proventys, a healthcare technology firm whose technology was acquired by McKesson Corporation. Before joining Proventys, he was Chief Medical Officer and Senior Vice President of Clinical Operations at D2Hawkeye, and worked as a healthcare strategy consultant at McKinsey and Company.

He is licensed and board certified in internal medicine. He continues to care for patients as a Hospitalist at Brigham and Women’s Hospital, and is also Adjunct Professor of Medicine at Harvard Medical School.

Rajanish Singla, MD

Chief Medical Officer, Radiation Therapy, eviCore Healthcare

Rajanish Singla is Chief Medical Officer, Radiation Therapy, at eviCore Healthcare, where he is responsible for guiding a 15-physician medical reviewer program as part of a multibillion-dollar specialty benefits management organization, and catalyzes program innovations of newly launched and transformative value-based medicine programs focused on establishing an alternative payment model. He also spearheaded ad-hoc projects that focus on driving enhancements and efficiencies to the company’s Radiation Therapy Program.

Prior to eviCore Healthcare, Dr Singla was Radiation Oncologist for Oncology Hematology Care, Director of the Center for Radiation Oncology at Metropolitan Urological Specialists, and Assistant Professor in the Department of Radiation Oncology at George Washington University Hospital.

Dr Singla received his Bachelor of Science degree summa cum laude from Kent State University, and his medical degree from Northeastern Ohio Universities College of Medicine. He completed his internship in internal medicine at Christ Hospital in Cincinnati, OH, and his residency in radiation oncology at Loyola University Medical Center, Maywood, IL.

Stan Skrzypczak

Vice President, Global Market Access, Guardant Health

Stan Skrzypczak is currently Vice President of Global Market Access for Guardant Health, a global leader in the field of circulating tumor DNA sequencing. He is now extending his expertise in reimbursement and global market planning to concentrate his efforts internationally in Europe, Canada, and Latin America after a successful US Medicare approval for the Guardant flagship product, Guardant360.

Prior to Guardant Health, he was Vice President of Business Development for Invitae, a germline next-generation sequencing company, and led marketing for Genomic Health’s franchise product, OncotypeDx Breast Cancer Assay. Prior to Genomic Health, he held multiple roles at Genentech in sales, marketing, reimbursement, and commercial development.

He received his Bachelor of Arts degree in biochemistry and molecular biology from the University Rochester, his Master of Business Administration in marketing from Xavier University, and his Master of Science degree in microbiology and immunology from Wright State University.

Alfred E. Slanetz, PhD

Founder, President, and Chief Executive Officer, Geneius Biotechnology

Alfred E. Slanetz is Founder of Geneius Biotechnology, and has been President, Chief Executive Officer, and a Director of the company full-time since its inception.

Prior to founding Geneius, he served as Chief Executive Officer and President of Bluebird Bio. Under his leadership, the company developed the leading lentiviral gene therapy platform, GMP manufacturing process, and accomplished the first curative therapy of a patient with gene therapy making a child with thalassemia who required transfusions every 2 weeks, transfusion independent 10 years and going.

He licensed the lentiviral product for adrenoleukodystrophy (which corrects the genetic cause of this lethal brain disease of children preventing progression).

Prior to Bluebird, he was Corporate Development Advisor for ESBATECH and Senior Vice President, Corporate Development, for Fovea, which were sold to Alcon (Novartis) and Sanofi, respectively. He served as Vice President, Business Development of TRANSGENE, where he closed licensing deals with Merck (Schering Plough) and Human Genome Sciences, and completed a $100 million IPO on NASDAQ and EuroNext. Before that, he served as Director, New Product Planning and Development, at Genentech, where he served as a key member of 5-person Core Development Teams for Herceptin, Rituxan, Avastin, Xolair, Lucentis, and In-Licensing Team for Rituxan. He was instrumental in co-development of diagnostics for Herceptin, resulting in the first product approved with a biomarker diagnostic and first personalized/precision therapy. He oversaw the Annual Long Range Plan for Genentech and wrote the first Commercial Plan for Genentech BioOncology.

He received his Doctor of Philosophy degree in molecular and immunobiology from Yale University.

Jayson Slotnik, JD, MPH

Principal and Co-Founder, Health Policy Strategies

Jayson S. Slotnik is Principal and Co-Founder of Health Policy Strategies, a Washington, DC–based consulting firm representing innovative biotechnology, pharmaceutical, device, and diagnostic companies. Prior to establishing Health Policy Strategies, he served as Vice President, Reimbursement and Innovation Strategies, United BioSource Corporation, where he was responsible for developing technology-related marketing and sales strategies for current internal and new external customers in the branded specialty pharmaceutical space. He partnered with the business development team to market technology strategies to more than 20 branded specialty manufacturers. In addition, he maintained his policy practice, which helped distinguish United BioSource Corporation’s market access technology as well as affording his clients the ability to have the business drive the policy and not the reverse.

Before joining United BioSource Corporation, Jayson practiced law at 2 prominent Washington, DC, law firms, where he counseled clients on many complex healthcare regulatory and legal issues related to coverage, coding, and reimbursement. Before returning to private practice, Jayson served as the initial Director, Medicare Reimbursement and Economic Policy, Biotechnology Industry Organization, the industry’s leading advocacy group. He served as the liaison between Biotechnology Industry Organization and the US Congress, Centers for Medicare & Medicaid Services, and other federal agencies to implement market access policies that stimulate and reward innovation while maintaining appropriate patient access to cutting-edge therapies.

He specializes in, and counsels clients on, the impact that Medicare and Medicaid coverage, payment, reimbursement, coding, and government policies have on commercial success. He also has experience as a healthcare strategist with demonstrated success in developing and implementing pre- and postlaunch strategies as well as life-cycle management tools for pharmaceutical, biotechnology, diagnostic, and device manufacturers.

He serves on the editorial boards for Value-Based Cancer Care and Specialty Pharmacy Times. He speaks regularly at various healthcare reform and market access conferences.

He received a Bachelor of Arts degree in English from the University of Rochester, his Master in Public Health with a concentration in epidemiology and biostatistics from George Washington University, and his Juris Doctor degree in health law from the University of Maryland School of Law.

Ipsita Smolinski, MBA, MPH

Managing Director, Capitol Street

Senior Strategic Advisor, McCallister & Quinn

Ipsita Smolinski has more than 20 years of diversified healthcare experience, principally in US healthcare policy research and consulting. As Managing Director of Capitol Street and Senior Strategic Advisor to McCallister & Quinn, she provides analysis of key healthcare trends and major developments. These include healthcare legislation moving on Capitol Hill, policies from the Centers for Medicare & Medicaid Services, US Food and Drug Administration, National Institutes of Health, and other agencies, as well as emerging politics. Her primary focus is forecasting the business implications of health policy through data-driven analysis.

She is an expert on prescription drug, supply chain, generic, biosimilar, and medical device reimbursement, bundled payments, Medicare Advantage policies, Medicaid expansion, and managed care policies, as well as acute care hospital and postacute payments. She works on the Precision Medicine, Cancer Moonshot, and other government public–private initiatives. She is close to Obamacare/Trumpcare and tax-related legislative initiatives, as well as healthcare consolidation and monitors other trends—commercial, Medicare, and Medicaid—in the healthcare industry.

Prior to launching Capitol Street in 2009, she was Senior Equity Research Analyst for Healthcare Policy at J.P. Morgan. Before joining J.P. Morgan, she advised clients on health policy and business trends at Citigroup and Bear Stearns.

Earlier in her career, she spent several years as a healthcare management consultant at the Lewin Group, a Washington-based firm specializing in managed care and healthcare payment policy, and worked at both Pfizer and the Centers for Disease Control and Prevention.

She holds a Master in Business Administration and a Master in Public Health from Columbia University and received her Bachelor of Arts in public health from Johns Hopkins University.

Mark Soberman, MD MBA FACS

Medical Director, Oncology Service Line; and Chief Physician Executive, Monocacy Health Partners at Frederick Regional Health System

Mark Soberman is Medical Director of the Oncology Service Line and Chief Physician Executive, Monocacy Health Partners at Frederick Regional Health System. He is Immediate Past President and member of the Board of Trustees of the Association of Community Cancer Centers.

He has served as Vice-Chair of the Department of Surgery; Director, Section of Thoracic Oncology; and Director, Section of Thoracic Surgery at MedStar Washington Hospital Center, and as Director, Division of Thoracic Surgery at Georgetown University Hospital. His academic appointments include Clinical Associate Professor of Surgery at Georgetown University School of Medicine and Clinical Assistant Professor of Surgery at George Washington University School of Medicine. His professional interests include the study of value-based healthcare, innovative care delivery models and innovative payment models, value in oncology, and multidisciplinary cancer care models.

He is a graduate of Washington University in St. Louis, Emory University School of Medicine, and the Darden School of Business at the University of Virginia. He completed his surgical training at the Emory University Affiliated Hospitals, George Washington University, and the Cleveland Clinic.

David Spetzler, MS, MBA, PhD

___Credials___

___Bio___

Eric Sredzinski, PharmD

Executive Vice President, Clinical Affairs and Quality Assurance Pharmacy Program, Avella Specialty Pharmacy

Eric Sredzinski is Executive Vice President, Clinical Affairs and Quality Assurance Pharmacy Program, at Avella Specialty Pharmacy, where he is responsible for the clinical management, disease state management, training, and implementation of patient adherence and persistence programs. Working closely with the company’s oncology, infectious disease, and transplant teams for presentations and business development, Dr Sredzinski, a member of Avella Specialty Pharmacy’s top management since joining the company in 2001, is also responsible for the management of manufacturer-contracted data sets, including participation in the development and testing of data layout.

Graduating with a Doctor of Pharmacy degree from the University of Arizona College of Pharmacy in 2000, he focused his training in oncology and infectious disease. Following a pharmacy internship at Tucson Medical Center, he completed his pharmacy practice residency at the Southern Arizona VA Medical Center, Tucson, where he worked with the oncology team and the prostate and neurologic cancer department. He worked as Clinical Pharmacist for Arizona Oncology’s Autologous Peripheral Stem-Cell Transplant Team, where he assisted in the medication management of all pre- and posttransplant patients.

He is an active member of the American Society of Health-System Pharmacists, The Arizona Pharmacists Association, Hematology/Oncology Pharmacy Association, American Society of Clinical Oncology, and American Academy of HIV Medicine, where he is HIV Pharmacist certified. He is currently involved in a National Institutes of Health clinical trial evaluating adherence and persistence in patients with a renal transplant that was recently presented at the American Transplant Congress and has been accepted for publication. Additional research in attention-deficit/hyperactivity disorder, the management of anticoagulated patients, and trends in antidepressants have been presented. He currently presents to local, regional, and national organizations on a number of health topics, including adherence and persistence. He is also active in community education, and has frequently presented to HIV and organ transplant groups.

Josh Stein, MBA

Chief Executive Officer and Co-Founder, AdhereTech

Josh Stein is Chief Executive Officer and Co-Founder of AdhereTech, a company that makes patented smart medication bottles to track and improve adherence for patients on specialty medications. AdhereTech’s smart bottles are currently distributed from most of the largest specialty pharmacies in the United States, and they are used for many of the top specialty medications as well. On average, AdhereTech improves adherence by approximately 20% and time on therapy by more than 30%.

Josh has been a featured speaker at TEDMED, National Institutes of Health, Cleveland Clinic Medical Innovation Summit, South by Southwest, and many other health and technology conferences.

He earned a Master in Business Administration from the Wharton School, University of Pennsylvania, and a Bachelor of Arts in economics, finance, and legal studies from Washington University in St. Louis, MO.

Charles A. Stevens, JD, MBA

Vice President and Global Lead, Access, Commercialization, and Communications, ICON

Charles “Chuck” Stevens leads ICON’s global Access, Commercialization, and Communications business unit, which includes MediMedia Managed Markets, Complete Healthcare Solutions, Pricing and Market Access Consulting, Health Economics & Outcome Research, and Patient Insight teams. The group consists of more 375 commercialization professionals.

He has 25 years of biopharmaceutical industry experience, including responsibility for strategic reimbursement, pricing, public and private payer strategy, HUB programs, product distribution/channel management, government price reporting, ex-US Health Technology Assessment submissions, and pharmacoeconomic modeling for both commercialized and noncommercialized products. He has specialized expertise in hematology, oncology, infectious disease, addiction medicine, central nervous system, and rare disorder/ultra-orphan drugs.

He has worked extensively on issues involving the Affordable Care Act, the Medicare Modernization Act of 2003, the Single Drug Pricer system, and obtaining product-specific Healthcare Common Procedure Coding System codes. In 2006, he was the first person to be successful in obtaining an individual product Healthcare Common Procedure Coding System from the Centers for Medicare & Medicaid Services (CMS) by making applications in advance of US Food and Drug Administration (FDA) product approval, resulting in the specific code being available at the time of product launch. He was a member of a biopharmaceutical consortium that successfully advocated for the Centers for Medicare & Medicaid Services’ expansion of recognized drug compendia supporting reimbursement and patient access to therapy in oncology.

Prior to joining ICON, he spent 9 years serving as Vice President and General Manager of PAREXEL’s Reimbursement and Market Access Consulting Practice. Previous to PAREXEL, he held commercial positions of increasing responsibility at the senior director level at Cephalon Oncology, Cell Therapeutics, Genetics Institute (Wyeth Oncology), and Abbott Laboratories.

He is a former Captain in the US Army Reserve and veteran of Operation Desert Storm. He is admitted to the Massachusetts Bar and the Supreme Court of the United States of America Bar. Chuck is a frequent presenter at international conferences, including the FDA/CMS Summit, and has been quoted in publications such as Barron’s, The Financial Times, PharmaVoice, FDA Week, and the Pink Sheet. He is a former member of the Government Affairs Committee of the National Association of Specialty Pharmacy and past member of International Society for Pharmacoeconomics and Outcomes Research’s Institutional Council and Comparative Effectiveness Research Workgroup. He is also a contributing editor for the Drug Information Association Global Forum.

He holds a Bachelor of Science degree in business administration from Northeastern University, a Masters in Business Administration from Clark University, and a Juris Doctorate from Suffolk University Law School. He also attended the Massachusetts Senior Executive Program at Harvard University’s John F. Kennedy School of Government.

Gretta Stone

Deputy Vice President, Policy & Research, Pharmaceutical Research and Manufacturers of America

Gretta Stone is Deputy Vice President of Policy & Research at Pharmaceutical Research and Manufacturers of America (PhRMA), where she works to communicate the positive contribution of biopharmaceutical companies and their products. She manages a range of issues related to the value of medicines, the research and development process, US Food and Drug Administration regulation, and personalized medicine. She has authored many PhRMA reports and publications, including the annual Biopharmaceutical Industry Profile, an overview of the sector and a go-to source of data on the industry; the Setbacks and Stepping Stones series on medicines that do not make it to approval, but pave the way for progress; and the Decade of Innovation series on advances in the fight against many diseases. In her more than 12 years at PhRMA, she has also worked extensively on orphan drugs, cancer, the biopharmaceutical pipeline, the research ecosystem, the cost of medicines, and marketing and promotion.

She serves on the Board of the Society for Women’s Health Research, an organization dedicated to advancing our understanding of the biological differences in disease and advocating to enhance women’s health. Prior to joining PhRMA, she worked in a lab researching language and the brain at Georgetown University, where she received a Bachelor of Science degree in biology.

Tricia Strusowski, RN, MS

Manager, Oncology Solutions

Tricia Strusowski is Manager of Oncology Solutions, a cancer-exclusive consulting firm with more than 40 years of experience, working collaboratively with healthcare professionals nationwide to implement comprehensive cancer care programs that enhance patient experience, improve hospital performance, and affect communities. With more than 34 years of experience in the oncology field, she has worked in a variety of roles, including an oncology nurse, nurse manager, case manager, and most recently, a clinical director overseeing a multitude of departments, including chemotherapy infusion, rehabilitation program, navigation, survivorship, multidisciplinary disease site centers, thoracic surgery, palliative care, oncology medical home program, wellness programs, and bone marrow coordinators and accreditation program.

Her passion is in navigation and patient- and family-centered care in the oncology landscape, and in conjunction with serving on multiple advisory boards, she implemented 15 multidisciplinary cancer centers, including breast, lung, head and neck, pancreatic, and various other tumor site–specific teams. She puts this rich work history to practice in consulting on the strategic development and implementation of oncology clinical programs within private practices, hospitals, and health systems across the country.

She has presented and published nationally and has participated in the development of oncology nurse navigator core competencies and the Academy of Oncology Nurse & Patient Navigators’ navigation metrics. She is Co-Chair of the American Cancer Society’s National Navigation Roundtable Evidence- Based Promising Practices.

She holds a Masters in healthcare administration and management from Wilmington University.

Sheila Talty, RPh, MBA

Healthcare Executive and Visionary Leader

Sheila Talty is a Healthcare Executive and Visionary Leader, frequently recruited for her ability to plan and execute major market expansion and bottom-line improvements, before and after the Affordable Care Act. Sheila possesses tenacious strategic focus on operational excellence and consistent earnings growth in a highly regulated industry.

She has been a key partner on senior management teams with in-depth experience in directing mission-critical sales, marketing, financial, and operational initiatives across commercial, pharmaceuticals, specialty pharmaceuticals, marketplace exchange, and product and business development at the Bayer Corporation and Anthem. She has identified and has built strategic collaborations with multiple stakeholders on a local and national scale.

She received her Bachelor of Science degree in pharmacy from the Philadelphia College of Pharmacy & Science, and holds a Master of Business Administration from the University of New Haven.

Michael Thompson

President and Chief Executive Officer, National Alliance of Healthcare Purchaser Coalitions

Michael Thompson is President and Chief Executive Officer of the National Alliance of Healthcare Purchaser Coalitions (National Alliance), an association of approximately 50 regional coalitions collectively supporting more than 12,000 healthcare purchasers providing health coverage to more than 45 million Americans. The National Alliance helps to lead improvements in health, well-being, and value for our companies and communities across the country.

Prior to joining the National Alliance, he was a Principal at PricewaterhouseCoopers for 20 years. He is a nationally recognized thought leader for business health strategies and health system reform, and has worked with major employers and other stakeholders on sustainable cost reduction, integrated health, wellness and consumerism, retiree health, private health exchanges, and health reform. Known for developing and promoting collaborative cross-sector health industry initiatives, he participated on the steering board of the World Economic Forum’s “Working Towards Wellness” initiative and co-founded the Private Exchange Evaluation Collaborative. Prior to PricewaterhouseCoopers, he served as an executive with diverse roles with Prudential Healthcare for more than 17 years.

He is a Fellow of the Society of Actuaries, serving on the Health Practice Council, and chairs the Medicare Subcommittee of the American Academy of Actuaries. He is also widely recognized as a leading national advocate for mental health and well-being and was Past President of the New York City chapter of the National Alliance for Mental Illness. He previously was an active member of the board of the Northeast Business Group on Health for 11 years.

Bob Tufts

Clinical Assistant Professor, Yeshiva University

Bob Tufts is Clinical Assistant Professor at the Sy Syms School of Business at Yeshiva University, where he teaches courses in the Business Strategy and Entrepreneurship Department. He was selected as the Teacher of the Year for the 2017-2018 school year.

He has a degree in economics from Princeton University, a Master of Business Administration in finance from Columbia University School of Business, and he worked on Wall Street for more than 20 years in futures and foreign exchanges and in domestic equities sales and trading.

Upon graduation from college he as a professional baseball player. He pitched in the major leagues during parts of the 1981-1983 seasons for the San Francisco Giants and the Kansas City Royals.

He is also a cancer survivor. He was diagnosed with multiple myeloma in 2009 and is currently participating in a clinical trial. He advocates for medical access to and choice in treatments on behalf of patients and doctors through My Life Is Worth It, an online not for profit he founded in 2013. He has written healthcare columns in the Huffington Post, speaks at and attends major medical conventions, and uses social media to ensure that the patient voice and narrative is included in healthcare discussion.

Sean R. Tunis, MD, MSc

Founder, President, and Chief Executive Officer, Center for Medical Technology Policy

Sean R. Tunis is Founder, President, and Chief Executive Officer of the Center for Medical Technology Policy in Baltimore, MD. The Center for Medical Technology Policy is an independent, nonprofit organization working to strengthen the quality, relevance, and efficiency of clinical research. His work currently focuses on expanding infrastructure for the conduct of pragmatic clinical trials within healthcare delivery systems, developing condition-specific evidentiary standards for reimbursement, and promoting greater engagement of patients and consumers in clinical research.

He serves as President of Health Technology Assessment International, and is a member of many other advisory boards for public and private sector organizations focused on issues of comparative effectiveness, innovation, health technology assessment, evidence-based medicine, clinical research, and reimbursement.

He received a Bachelor of Science degree in biology and history of science from the Cornell University School of Agriculture, and his Medical and Masters of Science degrees from the Stanford University School of Medicine. He completed his residency training at the University of California-Los Angeles and the University of Maryland in emergency medicine and internal medicine. He is board certified in internal medicine and holds adjunct faculty appointments at Johns Hopkins, Tufts University, and the University of California San Francisco Schools of Medicine.

Norris Turner, PharmD, PhD

Vice President, Strategic Alliances and Measure Implementation, Pharmacy Quality Alliance

Norris Turner serves in the role of Vice President, Strategic Alliances and Measure Implementation, at Pharmacy Quality Alliance (PQA). In this role, he leads PQA’s efforts to develop and maintain relationships at the regional, state, and federal levels with government agencies, commercial payers, providers, and pharmacies to further PQA’s measure development and implementation efforts. PQA, as a measure developer, seeks to partner with entities to improve patient care and to do so in a measurable way through appropriate inclusion of performance measures into value-based care measure sets.

Prior to joining PQA, he worked in the pharmaceutical industry for 19 years and served with Janssen over the last 12 years. His most recent position was Director, Health Care Quality, Neuroscience, within the Strategic Customer Group, Johnson & Johnson Health Care Systems, where he focused on the overarching quality and value-based care reimbursement direction in the United States.

Over a 15-year period, he held a variety of positions with increasing responsibility at Pfizer, Purdue Pharma, and Janssen in phase 2 to 4 clinical development and investigator-initiated research in the therapeutic areas of psychiatry and pain.

He obtained his PharmD degree from the University of Michigan College of Pharmacy. He obtained his PhD in pharmaceutical chemistry at the University of California San Francisco, and he obtained his 2-Year Graduate Certificate in Health Policy from Thomas Jefferson University School of Population Health. He was recognized by the Pharmaceutical Research and Manufacturers of America as a 2016 We Work for Health Champion. He currently serves as a Board Member for the National Transitions of Care Coalition.

Dr Norris lives in Yardley, PA, with his wife, Denise, and 3 high school and college-aged children, and is an avid runner.

F. Randy Vogenberg, PhD, RPh

Principal, Institute for Integrated Healthcare

Founding Partner, National Institute of Collaborative Healthcare

F. Randy Vogenberg is Principal, Institute for Integrated Healthcare, and Founding Partner, National Institute of Collaborative Healthcare, Greenville, SC. He focuses on employee commercial benefits, care delivery and outcomes research, and strategic benefit consulting on medical-legal, clinical, or economic issues. He is a healthcare expert on health-system delivery and economics, and health-related solution innovation research. He also currently serves as Co-Leader, National Employer Biologics & Specialty Initiative with the Midwest Business Group on Health.

He determined, designed, or developed higher efficiency and performing health services across the United States, and his work on employer benefits, or care delivery, has produced a number of books, papers, and presentations, and he continues to be the subject of articles and insight interviews about market changes or innovation.

He received his Bachelor of Science degree in pharmacy from the University of Rhode Island, his Master degree in management from Cambridge College, and his Doctorate in healthcare management from Century University.

Clorinda Walley

President, Good Days

Clorinda Walley is the President of Good Days, a charity that provides financial support by covering prohibitively costly copays for patients with life-altering conditions, allowing them to receive treatment without destroying their finances. She leads the charity with more than 20 years of experience in the healthcare industry and more than 8 years in strategic philanthropy. Clorinda effectively oversees the strategic and operational responsibility for the staff and programs for Good Days, as well as the expansion and execution of its mission. With in-depth knowledge of the organization’s core programs, operations, and business plans, Clorinda ensures the organization’s programmatic excellence. With her proven expertise, Clorinda has continuously ensured consistent quality of finance and administration, procurement of donations, internal and external communications, and development of all patient care initiatives.

Susan Weidner, MS

Senior Vice President, Analytics, IntrinsiQ Specialty Solutions

Susan Weidner is Senior Vice President, Analytics, at IntrinsiQ Specialty Solutions, where she is responsible for overseeing data analytics/business intelligence, and the software development and implementation initiatives for oncology, urology, and multispecialty customers.

She has gained more than 20 years of healthcare and pharmaceutical experience through executive leadership positions at SafeNet Consulting, Inform Genomics, and MGI Pharma (now Eisai). She has led the design, development, and implementation of innovative healthcare solutions, including those driven by healthcare informatics. Leveraging her expertise in clinical and outcomes research along with health economics, she has assisted pharmaceutical companies, payers, and providers in demonstrating the value of their products and/or their organizations.

A graduate of Eastern Kentucky University, where she earned a Bachelor of Science in mathematics and statistics, she also holds a Masters in biostatistics from the Ohio State University.

William (Bill) Winkenwerder Jr, MD

Chairman, CitiusTech

Charmain and Chief Executive Officer, Winkenwerder Strategies

William “Bill” Winkenwerder is Chairman of CitiusTech, a global health information technology services and solutions company. In addition, he is Chairman and Chief Executive Officer of Winkenwerder Strategies LLC, a US based healthcare advisory and investment firm. He is one of the most influential and recognized leaders in American healthcare, with experience in medical care, healthcare finance, and health insurance operations. Dr Winkenwerder is also an expert on federal health policy and programs, and new technologies such as electronic health records. Currently, he works with leading private equity firms, and in addition to CitiusTech, serves as director or advisor for healthcare firms such as WPS Health Solutions, Net Health, Accreon, RXRevu, Wellthie, and several additional companies.

Previously, Dr Winkenwerder served as Chief Executive Officer of Highmark Health, a Pennsylvania-based diversified insurance and healthcare enterprise, with revenues of $17 billion, employing 38,000 people and serving 35 million individuals. There he led a transformation to create the third largest integrated healthcare delivery and financing network in the nation. Highmark Health operates Blue Cross Blue Shield plans in multiple states, and provides dental insurance, vision care, and other health service companies. Highmark Health also operates Allegheny Health Network, comprised of 7 hospitals and more than 2500 affiliated physicians.

From 2001 to 2007, Dr Winkenwerder served as Assistant Secretary of Defense for Health Affairs with responsibility for a $40 billion annual budget, 132,000 personnel, and 9.2 million beneficiaries worldwide. Before his service with the Department of Defense, he served in senior leadership positions at Blue Cross of Massachusetts, Prudential Healthcare, and Emory University. Dr Winkenwerder is a Fellow of the American College of Physicians and a board certified physician who has practiced primary care medicine.

As a thought leader, Dr Winkenwerder has been an advocate for preventative healthcare, evidenced based medicine, internet technology-based solutions, and consumer engagement. He has worked closely with many major US employers on their healthcare cost issues. He has been a leading health industry strategist, an advisor to presidential candidates, and a regular contributor to various news and media outlets. Bill Winkenwerder is unique national health care leader, an experienced executive and financial strategist, who deeply understands both the private and public health sectors, and the power of new innovative technologies to transform the industry.

A graduate of Davidson College and The University of North Carolina School of Medicine, Dr Winkenwerder received his Masters of Business Administration from The Wharton School, of The University of Pennsylvania.

Jedd Wolchok, MD, PhD

___Credials___

___Bio___

William Yoon, PharmD, MBA

Executive Director and Head, US Medical Managed Markets and Strategic Alliances, Sandoz Biopharmaceuticals

William Yoon joined Sandoz Biopharmaceuticals in September 2013 and currently serves as Executive Director and Head, US Medical Account Managed Markets and Strategic Alliances. He is responsible for leading and developing medical strategy with national managed market accounts and key national associations. In his prior role, he served as National Director, Strategic Alliances, where he served leading medical strategy for national associations. When joining Sandoz, he served as Director, Clinical Development and Medical Affairs, where he supported the Sandoz Biosimilars Clinical Development programs, developed the GCSF Medical Affairs Strategy, provided state legislation testimonies, and led the efforts of National Medical Managed Market strategic plan.

Prior to Sandoz, he was at Novartis Oncology, where he spent more than 10 years in a variety of positions. He had developed the strategy for the Medical National Account teams, was the medical lead for hematology, and responsible for facilitating cross‐functional alignment within the organization. He led and developed strategic and tactical vision for the development of National Research Network Initiative.

Prior to Novartis, he was Director, Pharmacy Operations for PharMerica, an AmerisourceBergen Company. He managed and directed 10 directors who managed more than 100 employees each. He has intensive training in medical education and contracting for national, regional, Medicaid, and county plans. He was a member of various Pharmacy and Therapeutics Committee boards and has extensive consulting experience. He has more than 5 years of experience as a teaching preceptor for students of the University of Arizona and Midwestern University School of Pharmacy. He was also Clinical Instructor for Pharmacy practice at the University of Arizona and Midwestern University.

Danielle Ziernicki, BS, RPh, PharmD

Head, Medical and Regulatory Affairs, The Dedham Group

Danielle Ziernicki, Head of Medical and Regulatory for The Dedham Group, a pharmaceutical strategy consulting firm, has more than 18 years of pharmaceutical business experience. Prior to her current position, she spent more than 17 years working at Johnson & Johnson in various superior roles. After completing a postdoctoral residency in drug information at Janssen, she began in the Janssen Medical Information Department, serving as a strategic partner to sales and marketing organizations by providing scientifically accurate medical information for marketed products. Next, she transitioned to Janssen Global Regulatory Affairs and worked for almost 10 years as Director in the Global Regulatory Policy and Intelligence Department. After completing the Jefferson Health Policy certificate program, she served as Health Quality Lead for Immunology and Oncology at Johnson & Johnson, ensuring company strategies aligned with the United States overarching quality and reimbursement direction.

In addition to pharmaceutical industry experience, she is currently Adjunct Regulatory and Clinical Marketing Professor at the University of the Sciences in Philadelphia. Her experience also includes retail and hospital pharmacy; she worked for 10 years as an on-call hospital pharmacist.

She is a licensed Pennsylvania pharmacist and received her Bachelor in Science and PharmD degrees at Philadelphia College of Pharmacy, University of Sciences. She completed her a postdoctoral residency in drug information at Janssen and holds a graduate certificate in health policy from Thomas Jefferson University School of Public Health.

Burt Zweigenhaft

___Credials___

___Bio___